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Throughout the human female menstrual cycle, the endometrial lining of the uterus 
transitions from a non-receptive proliferative state to a receptive secretory state. This 
transition is required to prepare the endometrium for an embryo to successfully implant. 
Transitioning of the endometrium is governed by various genes, but the cellular 
processes are poorly understood. Unfortunately, for some women this process is 
compromised, resulting in the endometrium being inadequately primed for implantation 
and conception repeatedly fails. This is known as recurrent implantation failure (RIF). 
The aim of this study was to identify different markers within the functionalis layer of the 
endometrium that are important for implantation success.  
Qualitative and quantitative protein analysis was used to compare endometrial tissue 
biopsies between women with different fertility phenotypes. Biopsies were collected 
from women attending a single fertility clinic, with collection completed during the early-
secretory (pre-receptive LH+2) phase of the menstrual cycle. Cryo-sectioning was used 
to cut tissue sections, revealing glandular epithelium, luminal epithelium, and stromal 
cells. Immunofluorescence and SDS-PAGE combined with Western blots were used to 
assess protein expression. Expression levels of 25 different proteins previously reported 
to be involved in endometrial proliferation that feature in endometrial focal adhesion or 
cell cycle pathways were compared between four cohorts; Fertile (n=5), RIF(n=6), 
Research (n=6), and Other (n=4). Quantitative PCR was also used to detect relative mRNA 
expression levels in the endometrium between the internal references (ACTB and CYC1) 
and the target genes (EGFR, PCNA, PGR, and MCM2).  
It was found that endometrial protein profiles differ during the early-secretory, LH+2, 
phase of the menstrual cycle, between women who are fertile and women with clinically 
defined RIF. Immunofluorescence results showed a statistically significant increase of 
CCNA, PCNA, MKI67, and SMAD3, and decrease of IL1R1, in the fertile cohort in 
comparison to the RIF cohort. Western blot also showed statistically significant up-
regulation of PCNA in the fertile group, as well as PGR and YWHAZ. Gene expression 
profiles did not differ between fertile women and women with RIF, however there was a 
significant reduction of PGR and PCNA in the Research and Other groups in comparison 
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to the Fertile and RIF groups. In this pilot study, protein and gene analysis was able to 
detect alterations of expression in groups of women with different fertility phenotypes. 
Further exploration of these markers could help determine their possible role in 
endometrial dysfunction in RIF women and establish a clinical panel to indicate 
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Human reproduction is a complex process that, in females, is controlled by the menstrual 
cycle (1), which involves interactions between the endocrine system, glands, and 
reproductive tissue. The female contribution requires a mature oocyte (egg) and a 
primed endometrium (2), which are regulated by different hormones. For implantation 
of a fertilised oocyte to occur, specific events need to occur between the oocyte and the 
endometrium which involves the actions of hormones and proteins (3). Disruption of 
these important processes can lead to failure of implantation or pregnancy. 
 
1.1 The uterus and endometrial regeneration 
 
The uterus is a three-layered muscle that forms the reproductive cavity in women. Its 
anatomy consists of the external perimetrium, the intermediate smooth muscle 
myometrium, and the internal endometrium (4). The endometrium is comprised of the 
luminal epithelium, glandular epithelium, stromal fibroblasts, and vascular 
compartments (5), and is composed of two functionally different layers: the basalis layer 
which is the inner most layer that forms the junction between the endometrium and the 
myometrium, and then there is the outer functionalis layer (6). The basalis layer remains 
constant throughout the uterine cycle, while the functionalis layer is transient and is shed 
during the menstrual bleed (7). For this transient behaviour to occur, the endometrium 
needs to be able to regenerate after menstruation, which involves complex processes that 
include proliferation and angiogenesis (8). This regeneration of the endometrium occurs 
around 450 times throughout a woman’s life (9).  
 
1.2 The ovarian cycle and the menstrual cycle 
 
A three-phase menstrual cycle runs in parallel with the two-phase ovarian cycle (Figure 
1.1). Sex hormones produced by the hypothalamus, pituitary, and the gonads facilitate 




Figure 1.1: Physiology of the ovarian cycle and menstrual cycle. 
Sex hormones are involved in controlling the ovarian and menstrual cycles in females. Luteinising hormone and 
follicular stimulating hormone are important for the production of a mature oocyte and surges of these two hormones 
stimulate ovulation. Oestrogen and progesterone are important for the preparation of the endometrium for 
implantation as well as the shedding of the endometrial lining if implantation does not occur. (Figure from (10)). 
 
 
1.2.1 Hormonal control of the menstrual cycle and the ovarian cycle 
 
The four main sex steroid hormones involved in the menstrual and ovarian cycles are 
follicle stimulating hormone (FSH), luteinizing hormone (LH), oestrogen (E2), and 
progesterone (P4) (11). The first two hormones are gonadotropins produced by the 
anterior pituitary gland, while the latter two hormones are ovarian hormones produced 
by the ovaries. These hormone levels fluctuate depending on the time of the cycle (12). 
FSH is involved in follicle maturation within the ovaries, while a mid-cycle surge of LH 
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stimulates ovulation. These two hormones do not directly influence the endometrium, 
while E2 and P4 are directly responsible for controlling the transient cycle of the 
endometrium, and are discussed in section 1.3.  
 
1.2.2 The ovarian cycle 
 
The ovarian cycle can be sub-divided into three distinct phases; the follicular phase, 
ovulation, and the luteal phase. The follicular phase is a period of ovarian follicle 
development, where some of the follicles in the ovary mature to a Graafian follicle (13), 
under the influence of hormones, mainly FSH and E2. Later there is a surge in both LH and 
FSH, which results in ovulation 34 to 35 hours later (14). Ovulation is followed by the 
luteal phase, where the corpus luteum develops and subsequently produces P4 (15). 
During the luteal phase, fertilization and implantation can occur.  
 
1.2.3 The menstrual cycle 
 
The first phase of the menstrual cycle is menstruation, or shedding of the functionalis 
layer of the endometrium, which results from a decrease in P4 levels (16). Phase two is 
the proliferative phase, a period of significant growth of the endometrium, resulting from 
an increase in E2 levels (17). Ovulation occurs mid-cycle which separates the proliferative 
phase from the secretory phase. The secretory phase occurs post ovulation and is 
associated with increased levels of P4, which prepares the functionalis layer to become 
receptive for implantation of a blastocyst (15).  
 
1.2.4 Luteinizing hormone as a reference 
 
Mid-cycle, there is a significant surge of LH, which is known as LH+0 (18). During in-vitro 
fertilisation (IVF), it is important to know which phase of the menstrual cycle a women is 
at for planning of treatments, such as egg retrieval. To assist with this, the mid-cycle LH 
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surge is used as a reference (19), or for some cases human chorionic gonadotropin is used 
to manipulate ovulation and mimic LH (20). LH levels double from the baseline level to 
be in excess of 15 international units per litre, and is correlated with the opening of the 
ovulatory window (21), triggering ovulation 34 to 35 hours later (22). After ovulation, 
the endometrium transitions to a receptive state for implantation of the fertilised oocyte. 
The window of implantation (WOI) is the time where the endometrium is most receptive 
to the blastocyst (23), for a 4 to 5 day period (24), categorized as days LH+6 to LH+10, 6 
to 10 days after the initial LH surge of a normal menstrual cycle (25). 
 
1.3 The role of ovarian hormones and their receptors 
 
E2, P4, and androgens are sex hormones that are essential for endometrial development 
and for priming the endometrium for the implantation window. E2, P4, and androgens 
function through the plasma membrane nuclear receptors; oestrogen receptor alpha 
(ERα) and oestrogen receptor beta (ERβ), progesterone receptor (PGR), and androgen 
receptor (AR), respectively (26). 
PGR, which has alpha and beta isoforms, is located in the endometrial epithelial and 
stromal cells (27). It has a range of roles including involvement in cell communication, 
signalling, and transduction pathways (28). During the menstrual cycle, PGR levels 
fluctuate where there is up-regulation in the proliferative phase and down-regulation in 
the secretory phase (Table 1.1) (26, 29, 30).  
It has been reported that E2 and P4 have an intercalated relationship. Exposure of P4 is 
required for embryo implantation to occur, but for the P4 surge to occur, there needs to 
be a period of high levels of E2 (26). ER levels are increased in the proliferative and early-
secretory phase, which leads to cell proliferation (Table 1.1) (30, 31). ERα and ERβ have 
been shown to have different expression patterns throughout the glandular epithelium 
and stroma in the functionalis layer of the endometrium, depending on the phase of the 
menstrual cycle (31). Several studies have indicated that E2 is involved in increasing the 
proliferation of glandular endometrial epithelial cells, while P4 is involved in decreasing 
the epithelial cell proliferation induced by E2 (32-35). This is required to control 
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proliferation of the endometrium, and to increase uterine receptivity in the secretory 
phase (35).  
Androgens function through the AR (36), and both androgens and AR are expressed in 
the endometrium throughout the menstrual cycle (37). AR is expressed differentially 
throughout the endometrium and menstrual cycle, and around the time of ovulation, 
there is an increase in androgen levels. AR is involved in cell proliferation, cell 
communication, and cell-cell signalling pathways (31). One study has reported that there 
is no difference in AR expression between the proliferative and secretory phases of the 
menstrual cycle (38). More recent studies have suggested that there is greater AR 
expression in the proliferative phase compared to the secretory phase, in particular the 
late secretory phase (Table 1.1) (37, 39-41). During the secretory phase, stromal cells 
have the greatest amount of AR expressed in the nuclei of the functionalis and basalis 
layers of normal functioning endometria, while there is none or weak AR expression in 
the luminal and glandular epithelium (37, 40, 41). AR expression appears to be controlled 
by E2 and P4, where E2 is involved in up-regulation of AR while P4 is involved in inhibition 
of AR (39, 41-43). A function of AR is to counteract the proliferative effects, such as that 
of PGR, ERα, and ERβ, in the endometrium (41), by being involved in the arrest of mitosis 
and endometrial degeneration (39). Gregory et al (44) also reported that over-expression 
of AR negatively impacts endometrial function.  
The correct balance of P4, E2, androgen, and their receptors is essential for endometrial 
function. If the levels of any of the three hormones or their receptors are incorrect during 
the secretory phase, expression of proteins such as VEGF can be supressed or over-
expressed at this time (44). A recent study on PGR levels in fertile and infertile women 
has shown that infertile women have decreased PGR in the endometrial epithelial cells 
during the WOI (45). Leach et al (46) have reported a delayed reduction of PGR during 
the secretory phase, which led to over expression of PGR during the WOI, in infertile 
women. Reduced expression of ERα has been shown to be associated with women who 
have recurrent implantation failure (RIF), discussed in section 1.5.1, and thus the down-





1.4 The relationship between the endometrium and the blastocyst 
 
As well as the correct balance of ovarian hormones, endocrine, paracrine, and autocrine 
systems are also required for successful reproduction in females (48, 49). This can 
manifest as regular menstrual cycles (50, 51). If these systems operate correctly, an 
oocyte is produced which can be fertilised by a spermatozoon. Once fertilized, the oocyte 
can undergo several mitotic divisions, which will form the differentiated blastocyst (52).  
Embryo implantation is governed by an interaction between the blastocyst and the 
receptive endometrium (2, 3), which is a fundamental process for pregnancy to occur. For 
implantation to take place, the endometrium needs to go through a complex series of 
changes and requires numerous factors in order for it to become receptive to the invasive 
blastocyst (25). The luminal epithelium is the first point of contact for the blastocyst, and 
thus the luminal cells need to transition from a non-receptive to receptive state (53-55). 
If this transition does not occur, or if the processes controlling the relationship between 




Infertility is a phenomenon that is experienced by nearly 50 million couples worldwide 
(57). Fertility New Zealand (58), define infertility as “the inability to achieve conception 
after one year of unprotected intercourse, or the inability to carry a pregnancy to full term 
resulting in a live birth”. There are large gaps in the literature regarding the causes of 
infertility, even though it is a highly researched topic. Globally, 30% of couples with 
clinically defined infertility are classified as having unexplained infertility (59). Women 
in particular have a high prevalence of unexplained infertility, and for many of these 
cases, RIF is a common cause of their infertility, due to blastocyst-endometrium 
relationship failure. A definition of RIF is when clinical pregnancy cannot be achieved in 
four embryo transfers, over three or more cycles using assisted reproductive technology 
(60). Roughly one third of implantation failures are a result of embryo inadequacy, while 
around two thirds of implantation failures are a result of poor uterine receptivity (61). 
Consequently, IVF has become a popular technique used by couples to help achieve 
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pregnancy. Unfortunately, the success of IVF is low; on average 20% of IVF cycles are 
successful, which is thought to be due to implantation failure or poor embryo quality (62). 
More research is required in order to determine the underlying causes. Furthermore, 
additional information on the causes of infertility could be important for determining 
which different IVF treatments or assisted reproductive techniques to use. For IVF, eggs 
are retrieved on day LH+2, and in vitro procedures are completed, which is followed by 
embryo placement back into the uterus on day LH+7 (7 days after the initial LH surge). If 
all reproductive mechanisms are operating normally, then this will lead to successful IVF.  
 
1.5.1 Recurrent implantation failure 
 
Unfortunately, mechanisms important for implantation are not always functioning 
adequately and so implantation fails. Implantation failure during IVF is very common, as 
only 20 to 30% of embryo transfers lead to successful pregnancy (63-65). There is poor 
availability of resources and research outcomes on why this rate is so low. There is a 
whole range of factors that appear to contribute to implantation failure, which may 
include embryo inadequacy, poor uterine receptivity, failure of the embryo and uterus to 
communicate, and genetics (66, 67). Of the women with implantation failure, or RIF, two 
thirds have poor endometrial receptivity, while one third have embryo inadequacy (61, 
68). It is thought that differences in gene expression in the endometrium is a major factor 
in implantation failure (47, 69, 70). Gene expression alterations in the endometrium may 
impact cellular growth, proliferation, and even angiogenesis, and therefore endometrial 
receptivity. Genes involved in the cell cycle are responsible for this cellular growth and 
proliferation (71), and consequently alterations in expression of these genes could 
impact reproductive outcome (67, 69, 72).  
The definition of RIF has been debated, and has considerable variation throughout the 
literature. An initial definition of RIF was failure to achieve pregnancy after the transfer 
of 12 embryos over multiple cycles (73). A later survey defined RIF as three failed viable 
embryo transfers, over three cycles (74, 75). This appeared to be the most popular 
definition at the time. Another definition in use was failure to achieve implantation and 
consequential pregnancy after four or more cycles with viable embryos, or ten or more 
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embryos transferred over multiple cycles (76). Rinehart et al (77) defined RIF as 
pregnancy not achieved after either eight or more eight-cell embryos, or five or more 
blastocyst transfers. There is now a universal definition of RIF which is four failed embryo 
transfers, over three or more IVF cycles (60).  
 
1.6 Markers in the endometrium and their association with endometrial 
preparation 
 
Numerous factors in the endometrium have been reported to be associated with 
endometrial receptivity. These factors are associated with a wide range of processes 
including development and maintenance of the endometrium. Extracellular ligands such 
as insulin-like growth factor (IGF1), transforming growth factor alpha (TGFα), and 
vascular endothelial growth factor (VEGFA) are involved in important processes such as 
proliferation, and have other functions including; cell growth, differentiation, 
development, induction of endothelial cell mitosis, and angiogenesis within the 
endometrium (78). Additionally, insulin-like growth factor receptor 1A (IGF1RA), 
platelet-derived growth factor receptor alpha (PDGFRα), and vascular endothelial 
growth factor receptor 2 (VEGFR2) are some of the tyrosine kinase receptors present on 
the cell membrane, with extracellular ligands that play an important role in the above 
mentioned processes (79, 80).  
Preliminary work by the Laboratory for Cell and Protein Regulation (LCPR) group 
(University of Otago, Christchurch) examined genes which are active in the endometrium 
during the receptive phase of the menstrual cycle (71, 81). Using laser microdissection of 
endometrial glandular epithelium, stroma, and luminal epithelium, along with 
microarrays, Evans et al (71) reported that 60% of the genes that they identified as active 
in the receptive phase of the menstrual cycle had not been previously reported in the 
context of endometrial receptivity. Previous studies have focussed on whole tissue (82-
85), rather than micro-dissected tissue. The cell cycle (Figure 1.2), which controls mitosis 
(71), was identified as being important through analysis of microarrays by comparing the 
non-receptive (LH+2) and receptive (LH+7) time points. Evans et al (71) explored this 
pathway further to establish protein expression profiles of women who achieved 
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successful implantation compared with women who were unable to achieve 
implantation. It was identified that the women who could not achieve implantation had 
reduced or negative expression of some of the proteins that the women who achieved 
successful implantation expressed. This led to the suggestion that women who were 
unable to achieve successful implantation had inadequate endometrial proliferation, 
causing failure of implantation. Subsequent research has further evaluated the 
involvement of proteins reported as essential for adequate proliferation, although there 
is limited literature available on these factors. These potential protein markers of 
endometrial adequacy for implantation will be discussed below, and are summarised in 
Table 1.1 and Figure 1.2. 
 
 
Figure 1.2: Key elements of the cell cycle pathway in humans.  
The cell cycle, which is a pathway that results in mitosis or proliferation, is likely to be an important pathway for 
endometrial proliferation. This figure shows many markers that were analysed in this study (red circles), and shows 




Table 1.1: Markers in the endometrium and their expression throughout the menstrual cycle. 
Marker Proliferative Secretory 
Early Late Early Late 
PGR     
ER    
AR    
CDKN2A   LH+2 LH+7 
CDC6    LH+7 
MCM2    
PCNA   LH+7 
CCNA1    
EGFR     
FAK     
VEGFR   
MKI67    
IGF1     
IGF1RΑ  
IL1R1   
PDGF-RΑ   
TGFΑ    
TGFΒ     
VEGFA     
SMAD3     
Note: Markers that feature in the endometrium have differential expression throughout the menstrual cycle, 
depending on the function they serve. LH+2= pre-receptive secretory phase, LH+7 = receptive secretory, ↑ = up-
regulated at this time, ↓= down-regulated at this time. 
 
The roles of the factors in Table 1.1 and their implications for the endometrium are 
discussed in this section and in sections 1.7 and 1.8. PGR, ER, and AR have been discussed 
in section 1.3. 
Cyclin-dependent kinase inhibitor (CDKN2A) is a gene present in the endometrium, and 
is involved in controlling the cell cycle as well as in cell growth and death (87). CDKN2A 
messenger RNA (mRNA) is upregulated at LH+2 and down-regulated at LH+7 in 
preparation for the endometrium to become receptive (71). Evans et al (81) have 
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reported that CDKN2A is up-regulated in the luminal epithelium, which indicates that this 
epithelium is undergoing cell growth or death. CDKN2A, also known as p16, is a common 
tumour suppressor in the p53 signalling pathway. Mutations in this gene can lead to 
under-expression of this factor allowing inducement of cancer formation (88). This 
suggests that if there are mutations in the CDKN2A gene in the endometrium, then 
unusual mitosis may occur.  
Cell division cycle 6 (CDC6) and mini-chromosome maintenance complex (MCM) family 
of proteins are expressed in the endometrium. CDC6 binding to the recognition complex 
is necessary for the binding of certain MCMs, such as MCM2 (89). CDC6 is a protein 
involved in the cell cycle, and participates in cell growth and death (90, 91). Evans et al 
(71) have reported that CDC6 was down regulated in the glands during the receptive 
phase of the cycle (LH+7). MCMs have been described as good markers of proliferation 
(92), and are involved in DNA replication (5). MCM’s 2, 3, and 6 have been reported as 
down regulated during the LH+7 phase by Evans et al (71). MCM2 is increased in the 
proliferative and early-secretory phases (30, 35) and is a marker of proliferation.  
Proliferating cell nuclear antigen (PCNA) is present in proliferative cells within the 
endometrium, as well as other tissues (93, 94), and may be an important marker for 
determining endometrial proliferation adequacy . PCNA has been reported to have strong 
expression in the endometrium, particularly in the glands and stroma (95, 96). Evans et 
al (71) reported that PCNA was down regulated in the glands at the receptive LH+7 time 
of the cycle. This finding has been confirmed by others that have also identified greater 
expression of PCNA in the glandular epithelium, luminal epithelium, and the stroma in 
the proliferative phase (30). PCNA has a range of functions, including DNA repair and 
replication (95), which is important in the endometrium for mitosis and proliferation. 
PCNA appears to be the current preferred endometrial proliferation marker in both 
human and rodent studies (97, 98). Lai et al (98) demonstrated in rodents that PCNA is 
expressed during both the renewal and regression of the endometrium, and that PCNA is 
influenced by sex steroid hormones during the menstrual cycle. 
Cyclin-A (CCNA) is involved in regulating the cell cycle, and hence has an important role 
in endometrial mitosis (30). Over expression of CCNA has been reported in endometrial 
carcinomas, which is indicative of its role in mitosis (99). CCNA has greater expression in 
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the glandular epithelium and luminal epithelium in the proliferative phase (30), and is 
thus important for endometrial regeneration and potentially for endometrial receptivity. 
Epidermal growth factor (EGF) and its receptor (EGFR) are involved in cellular 
proliferation and growth in the endometrium (100), and are involved in regulation 
throughout the menstrual cycle (101). A preliminary study reported that EGF and EGFR 
have reduced expression during the proliferative stage, which increases prior to 
ovulation (102). Subsequently, Moller et al (101) also identified that EGF and EGFR were 
expressed differentially in the glands, stroma, and luminal epithelium throughout the 
menstrual cycle. EGF was primarily expressed in the glands during the mid-proliferative 
phase. EGFR was highly expressed by the glandular and luminal epithelium throughout 
the menstrual cycle, and by the stroma in the mid-late secretory phase. EGFR was 
upregulated as a result of E2, while there was no involvement of P4 (100, 102, 103). 
A more recently studied marker of endometrial proliferation, marker of proliferation 
(MKI67), is expressed in the nucleus of proliferating mammalian cells (104-106) during 
the active phases of the cell cycle, but absent during silent periods of the cell cycle (107). 
This suggests that endometrial cells that do not express MKI67 are not proliferating, and 
it may be a good marker with which to detect endometrial proliferation. MKI67 is 
differentially expressed during the different phases of the menstrual cycle (108), 
probably due to regulation by sex steroid hormones (109), and is associated with 
proliferation of the endometrium (110). MKI67 has been reported to be highly expressed 
in the endometrium during the proliferative phase of the menstrual cycle, in comparison 
to none to nil expression during the secretory phase (108, 111, 112). In accordance with 
these studies, Maia et al (113) looked at the glandular epithelium of the endometrium 
and identified that MKI67 is highly expressed during the proliferative phase, and around 
the time of ovulation the expression slowly diminishes to an undetectable level in the late 
secretory phase. Similar results were reported in a study that identified MKI67 
expression in the glandular and luminal epithelium during the proliferative phase, while 
during the secretory phase MKI67 reduced to an undetectable level by the late-secretory 
phase; expression of MKI67 remained constant in the stroma (110). 
IGF1 and its receptor IGF1RA are also involved in endometrial regulation (114, 115), by 
positive regulation of cell proliferation as well as the via extracellular signal-regulated 
kinase (ERK) mitogen-activated protein kinase (MAPK) signalling pathway (80). IGF1 is 
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differentially expressed during the different phases of the menstrual cycle (116). In 
response to E2, IGF1 increases in the stromal cells in the late proliferative phase and 
early-secretory phases of the menstrual cycle (117-119). The receptor, however, is 
expressed independently of the phase of the menstrual cycle and is relatively uniform 
throughout the whole cycle (114). 
Interleukin 1 receptor 1 (IL1R1) is a member of the cytokine receptor family, which is 
expressed throughout the reproductive system in humans (120), including the 
endometrium (121). IL1R1 may be important for inflammatory responses during the 
menstrual cycle. Simón et al (122) observed increased expression of IL1R1 during the 
secretory phase of the menstrual cycle, while another study by the same group also 
reported that IL1R1 is expressed in the endometrium throughout the entire menstrual 
cycle, with increased expression during the secretory phase (123). They elaborated on 
this and recognised that there was consistently strong IL1R1 expression in the luminal 
epithelium throughout the menstrual cycle, while in the glandular epithelium there was 
differential IL1R1 expression in the secretory phase compared to the proliferative phase 
(123). In another study, the authors reported the same phase-dependent expression 
pattern of the receptor, where there is low expression in the proliferative phase and 
expression increases from the mid to late secretory phase (124). There appear to be 
inconsistencies in the literature regarding the importance of IL1R1 in implantation 
success. One hypothesis is that IL1R1 expression is not associated with implantation, as 
it was reported that there was no difference in IL1R1 between women with different 
fertility phenotypes (124). Another hypothesis is that IL1R1 could be associated with 
implantation, as they reported IL1R1 is important for the endometrial-embryo 
interaction during implantation (123). IL1R1 could be an important factor for 
determining endometrial adequacy at the time of implantation.  
PDGFRα is another growth factor receptor present in the endometrium that contributes 
to regeneration of the endometrium during the menstrual cycle (125). The literature 
suggests that PDGF and its receptors are involved in inducing mitosis in the endometrium 
(126), which is important for the preparation of the endometrium prior to implantation. 
Munson et al (125) identified in cell culture that PDGFRα is expressed on epithelial cells 
of the endometrium, which is indicative of its role in mitogenic and cell proliferative 
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functions. Reduced PDFRRα during the early-secretory phase could cause failure of the 
endometrium to prepare for implantation.  
TGFα is involved in cell proliferation and regulation of the cell cycle in the endometrium. 
This growth factor is increased in the proliferative and early-secretory phases (80). 
Expression of TGFα is influenced by the expression of EGFR, where altered EGFR 
expression may also alter the expression of TGFα. TGFα also has a similar expression 
pattern in the endometrium throughout the menstrual cycle as EGF, where there is 
increased expression in the mid to late proliferative phase (102, 127). TGFα and EGFR 
are involved in mediating the growth of the endometrium throughout the menstrual 
cycle, and thus are potentially important for determining whether the endometrium is 
prepared for implantation. 
Transforming growth factor beta (TGFβ) is also expressed in the endometrium 
throughout the menstrual cycle (128). It appears to have an inhibitory regulatory role on 
the proliferation of epithelial cells (129), which opposes the action of TGFα, therefore, the 
ratio of TGFβ to TGFα is important for controlling the rate of proliferation. An initial study 
reported a uniform distribution of one of the TGFβ subtypes in the glandular epithelium 
and the stroma (130). Several other studies have reported that there is greater 
expression of TGFβ in the late secretory and early proliferative phases of the menstrual 
cycle, in comparison to the late proliferative and early-secretory phases (129, 131). 
Contradictory to these finding, another study reported that there was increased TGFβ 
expression in epithelial and stromal cells in the mid-secretory phase, as well as in the late 
proliferative phase (132). As TGFβ supposedly supresses’ proliferation, it would be 
intuitive to hypothesise that it would be increased during periods of low proliferation, 
such as the mid to late secretory phase.  
TGFβ mediates endometrial proliferation through mothers against decapentaplegic 
homolog 3 (SMAD3), which is another protein that features in the cell cycle (133). SMAD3 
is phosphorylated by TGFβ and consequently supresses proliferation in the endometrium 
(134). P4, which increases during the secretory phase, increases SMAD3 expression in the 
stromal cells of the endometrium, and therefore SMAD3 is also expressed preferentially 
in the secretory phase in comparison to the proliferative phase (135). Gonadotrophin 
releasing hormone (GnRH) and E2 are important for modulating SMAD3 expression, 
where GnRH and E2 exposure supresses the expression of SMAD3 and therefore increases 
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proliferation of endometrial cells during the proliferative phase (136). Over-expression 
of SMAD3 during periods of proliferation, as a result of subsequent P4 exposure, could 
disrupt the preparation of the endometrium prior to implantation.  
Polli et al (132) discussed the importance of appropriate protein expression in the 
endometrium, and that imbalanced protein expression could be a cause of implantation 
failure. Studying the protein markers described above, which are involved in endometrial 
proliferation and development, may be a good starting point to identifying where 
aberrant protein expression occurs, and why implantation is consequently failing.  
 
1.7 The focal adhesion pathway 
 
Preliminary work by the LCPR group has identified that some of the protein markers 
reported in Section 1.6 may be indicators of endometrial proliferation adequacy. They 
also reported that there are reduced expression levels of growth factors such as IGF1 and 
VEGFA, along with the tyrosine kinase receptors IGF1Ra, VEGFR2, PDGFRα, and focal 
adhesion kinase (FAK), in women with RIF. These proteins feature in the focal adhesion 
pathway, which will be discussed below.  
The focal adhesion pathway involves interactions between growth factors, or 
extracellular ligands, and their tyrosine kinase receptors on the cell membrane, where 
they bind (137). This results in the regulation of downstream processes such as 
transcription and therefore cell proliferation, via the FAK pathway (137). A reduction of 
these markers in women with RIF, is indicative of impairment of adequate endometrial 
growth and preparation during the pre-receptive secretory phase of the menstrual cycle 
(71). This provides evidence that ligands, and therefore their receptors, modulate the 
FAK pathway. This appears to be the first indication of functional relevance that low 
expression of these factors will alter function in the endometrium, suggesting that one of 
the components of infertility may be the dysregulation of the FAK complex.  
FAK, also known as protein tyrosine kinase 2, is a central factor present in the focal 
adhesion pathway, and is involved in integrin-mediated adhesion and signal transduction 
(138). FAK, along with phosphorylated FAK, which is the active form of FAK, have a whole 
range of functions including cell proliferation, motility, focal adhesion, and survival, and 
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also important for aiding in tissue repair and remodelling, structure, and function (139). 
Orazizadeh et al (139) have reported that FAK is up-regulated in the glandular, luminal, 
endothelial, and stromal cells during the proliferative phase, remains highly expressed in 
the early and mid-secretory phases of the menstrual cycle, and is then down-regulated in 
the late secretory phase; this is supportive of endometrial regeneration, preparation for 
implantation, and apoptosis respectively. Another study reported FAK expression as low 
to moderate in the endometrium during the proliferative phase (140), which is contrary 
to its established role in proliferation. 
MAPK, and also ERK, are regulated via the FAK complex. MAPK is important for cell 
survival and proliferation, where a cascade of events leads to the activation of MAPK, 
resulting in the phosphorylation of downstream transcription factors (141). Therefore, 
regulation of proliferation and differentiation of cells depends on MAPK expression. This 
could be an important factor for determining endometrial receptivity, however, this has 




Angiogenesis is a mechanism involved in development of new blood vessels in tissue 
(142). Angiogenesis is a complex process that tends to occur in utero; however, there are 
exceptions where angiogenesis occurs in adults, including wound repair, the menstrual 
cycle, and in some diseases such as in tumours (142, 143). Angiogenesis is essential 
throughout the menstrual cycle as the endometrium is regularly being shed and renewed. 
During the normal menstrual phase, vessel density and endothelial cell proliferation is 
relatively uniform (144-146). There are a range of growth factors present in the 
endometrium that mediate angiogenesis to enhance the endometrium (147), as discussed 
below.  
E2 and P4 are involved in the hormonal control of angiogenesis, both have been discussed 
as being either an inhibitor or inducer of angiogenesis (148). In the literature there is 
debate regarding whether E2 assists in angiogenesis via VEGF, or whether it has a direct 
inhibitory effect in the endometrium. There is evidence from a rodent study that E2 
inhibits angiogenesis in the endometrium; however, the study found that E2 increases 
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vascular permeability (149). Although P4 and E2 are important for general development 
and growth of the endometrium, they are not the primary inducers of angiogenesis or 
VEGFA expression in the endometrium (145). 
VEGFA is upregulated in the early-secretory phase (Table 1.1) (78, 80). VEGF is involved 
in positive regulation of cell proliferation, and is one of the growth factors involved in 
angiogenesis. VEGF appears to be the most important initiator of angiogenesis in the 
endometrium (101, 150-152), where it acts via its receptor, VEGFR, also known as kinase 
insert domain receptor or fetal liver kinase 1 (153). Greater expression of VEGF has been 
observed in the stroma during the early proliferative phase of the menstrual cycle (145). 
Another study identified that VEGF was preferentially expressed in the mid-secretory 
phase in the glands and stroma (103). In accordance with these studies, another two 
studies reported that VEGF and VEGFR begin to increase in the proliferative phase, 
reaching a peak in the secretory phase of the menstrual cycle (Table 1.1) (79, 154). 
Unpublished data from LCPR, showed that VEGFA was upregulated in the glands. 
Blood vessel growth is necessary for the development and maintenance of the 
endometrium and subsequent endometrial receptivity for implantation (155). Hence, 
women with RIF who have reduced protein levels of VEGFA and VEGFR are more likely 
to have reduced angiogenesis, leading to a decrease in proliferation adequacy. Reduced 
angiogenesis in the endometrium means that the supply of nutrients and oxygen to the 
tissue is also reduced, and if this is prior to the WOI opening, the endometrium is not 










1.9 Aims and Hypothesis 
 
Many studies have shown that endometrial preparation prior to the time of implantation 
is important for determining whether a blastocyst will adhere to the endometrium during 
the WOI. There are many factors present in the functionalis layer of the endometrium, 
and various papers suggest that some or many of these factors may participate in 
implantation success or failure. As the main focus of research on the endometrial 
contribution to implantation failure has been directed towards the receptive, LH+7, 
secretory phase, there is a lack of knowledge and understanding regarding whether the 
composition of the endometrium during the non-receptive, LH+2, phase is important for 
predicting implantation outcome. Preliminary work by the LCPR group, and others, has 
identified a range of potential endometrial markers associated with proliferation and 
subsequent endometrial receptivity, by comparing these markers in fertile women with 
women who have RIF (71, 81). Quality data about specific markers that define 
endometrial receptivity is needed to help develop knowledge and understanding on what 
is required to produce positive outcomes in IVF. 
We hypothesized that there is dysregulation of important markers during the LH+2 phase 
in women who have RIF in comparison to women who are fertile, which may lead to a 
negative pregnancy outcome. 
Fertility Associates, New Zealand, currently take endometrial samples from some 
women, particularly those with RIF, during the LH+2 phase of the cycle prior to the IVF 
cycle; this increases the odds of sustaining a full pregnancy two-fold by creating 
endometrial injury (156). These samples were used to study and compare the 
endometrial composition of women with RIF and fertile women. In this study, we aimed 
to: 
- Test whether endometrial protein and gene expression profiles differ between 
fertile women and women with clinically defined RIF. 
- Define which specific markers in the endometrium are important for endometrial 





2 Materials and Methods: 
 
2.1 Ethics and approval 
 
This study received approval from The Health and Disability Ethics Committees, New 
Zealand (reference 16/STH/10).  
 
2.2 List of antibodies 
Table 2.1: Table of antibodies used for Immunofluorescence and Western blot. 






used for Western blot) 
Anti-CCNA Anti-Cyclin A SC-751 Rabbit 54 
Anti-CDC6 Anti-Cell division control 
protein 6 homolog 




kinase inhibitor 2A 
SC-65476 Mouse  
Anti-PCNA Anti-Proliferating cell 
nuclear antibody 
SC-25280 Mouse 36 
Anti-SMAD3 Anti-Mothers against 
decapentaplegic homolog 
3 
SC-101154 Mouse  
Anti-AR Anti-Androgen receptor SC-13062 Rabbit  
Anti-ESR1 Anti-Oestrogen receptor 1 SC-7207 Rabbit  
Anti-FGF1 Anti-Fibroblast growth 
factor-1 
SC-55520 Mouse  
Anti-IGF1 Anti-Insulin-like growth 
factor 




factor 1 receptor 




growth factor receptor α 
SC-431 Rabbit  
Anti-PGR Anti-Progesterone 
receptor 
SC-538 Rabbit A-81 B-116 
Anti-TGFα Anti-Transforming growth 
factor α 
SC-36 Mouse  
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SC-9043 Rabbit  
Anti-TGFβ Anti-Transforming growth 
factor β 
SC-7892 Rabbit  
Anti-VEGFA Anti-Vascular endothelial 
growth factor 
SC-152 Rabbit  
Anti-KDR Anti-Kinase insert domain 
receptor 
SC-6251 Mouse  
Anti-IL1R1 Anti-Interleukin 1 
receptor, type 1 
SC-25775 Rabbit 80 
Anti-FAK Anti-Focal adhesion kinase SC-558 Rabbit  
Anti-FGF7 Anti-Fibroblast growth 
factor-7 
SC-7882 Rabbit  
Anti-MCM2 Anti-Mini-chromosome 
maintenance 2 
SC-10771 Rabbit 130 
Anti-EGFR Anti-Epidermal growth 
factor receptor 
SC-120 Rabbit  
Anti-ERK1/2 Anti-Extracellular signal-
regulated kinases 1 and 2 




SC-557 Rabbit  
Anti-MKI67  Anti-Marker of 
proliferation Ki-67 







Activation Protein Zeta 
SC-13959 Rabbit 30 













Horseradish peroxidase  
SC-2004 Goat  
GAR-ATTO Goat Anti-Rabbit-ATTO Sigma-Aldrich Goat   
SAM-FITC Sheep Anti-Mouse-FITC Sigma-Aldrich Sheep   
DAPI 4',6-diamidino-2-
phenylindole 
Thermofisher   





Solutions made up in the laboratory are described in the following section, while 
externally sourced reagent details are cited when used.  
  
10x Phosphate-buffered Saline (PBS) 
For 1 L: 800 ml Milli-Q water 
  80 g NaCl 
  2 g KCl 
  14.4 g Na2HPO4 
  2.4 g KH2PO4 
  pH adjusted to 7.4 with HCl 
  Total volume (1L) made up with milli-Q water  
 
Radioimmunoprecipitation assay (RIPA) buffer  
For 50 ml: 1.25 ml 50 mM Tris-HCl, pH 7.4 (2M)  
  0.29 g 100 mM NaCl 
  0.5 ml 100% NP-40 (1%) 
  0.25 g 0.5% sodium deoxycholate 
  0.05 g 0.1 SDS 
  0.093 g 5 mM EDTA (1mM)  
  5 ml 100% glycerol (10%) 
  42.62 ml milli-Q water  




SDS-PAGE 4x separating gel buffer (Solution B) 
For 50 ml: 37.5 ml 2 M Tris – HCl (pH 8.8) (1.5M)  
  2 ml 10% SDS (0.4%) 
  10.5 ml milli-Q water  
 
SDS-PAGE separating solution (10%) 
For 4 gels: 8.34 ml milli-Q water 
  5 ml 4x separating gel buffer 
  6.66 ml 40% acrylamide stock solution (Bio-Rad catalogue #161-0148) 
  100 µL 10%(NH4)2S2O8  
  10 µL TEMED   
 
SDS-PAGE 4x stacking gel buffer (Solution C) 
For 50 ml: 25 ml 1 M Tris-HCl (pH 6.8) (0.5M) 
  2 ml 10% SDS (0.4%) 
  23 ml milli-Q water 
 
SDS-PAGE stacking gel (7%) 
For 4 gels: 4 ml milli-Q water 
  2 ml 4x stacking gel buffer 
  2 ml acrylamide stock solution (Bio-Rad catalogue #161-0148) 
  80 µL 10%(NH4)2S2O8 




SDS-PAGE running buffer 
For 2 L:  6 g Tris 
  28.8 g Glycine 
  2 g SDS 
  Total volume (2 L) made up with milli-Q water 
 
Transfer buffer for Western blotting 
For 1 L: 1.93 g Tris 
  9 g Glycine 
  Total volume (1 L) made up with milli-Q water 
 
Tris-Buffer Saline plus TWEEN-20 (TBS-T) 
For 4 L: 40 ml 20 mM Tris-HCl (pH 7.5) (2 M) 
  32.72 g 140 mM NaCl 
  3.9 L milli-Q water   
  Autoclaved and cooled 
  4 ml Tween®-20 (Sigma life science) 
 
Blocking solution for Western blotting 
For 100 ml: 5 g skim milk (5%) 
  100 ml TBS-T 
  OR 
  1 g BSA (1%) 
  100 mL TBS-T 
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Coomassie Blue G-250 
  0.25% Brilliant Blue G-250 
  40% methanol 
  10% acetic acid 
  49.75% milli-Q water 
 
Coomassie destain 
For 1 L:  100 mL acetic acid 
  250 mL methanol 
  Total volume (1 L) made up with milli-Q water 
 
5x Sample buffer 
For 10 mL:  0.6ml 1M Tris-HCL (pH6.8) 
  5 mL 50% glycerol 
  2 mL 10% SDS 
  2 mL 1% bromophenol blue 









2.4 Study Participants  
 
Women aged between 20 and 45 years attending Fertility Associates, Christchurch were 
invited to participate in this study. Each participant was provided with an information 
sheet about the study along with a consent form, and written consent was obtained for 
their tissue samples to be used for research. In total 10 samples were obtained between 
May 2016 and October 2016. Women included were going through IVF and having an 
embryo transfer during the following cycle, had a BMI <30, did not smoke, and were 
taking no medication. 
Twenty-four banked Pipelle samples (section 2.5), collected as per current protocol, from 
2012 to 2014 were also included in the study sample. All banked samples were collected 
at the LH+2 secretory phase as determined by blood hormone levels of LH, E2, and P4. 
Biopsies were stored at -80°C in order to preserve the samples. Consistent results were 
observed when comparing immunofluorescence results from this study with those from 
previous analyses of the same samples. This indicated that there was negligible 
degeneration of the sample from when it was collected to the time of this study, and that 
the storage conditions were adequate.  
Banked samples and samples collected during this study were separated into four 
different research groups (Table 2.2). The first group was the control group, which 
comprised banked samples from five women with proven fertility (Fertile). Five banked 
samples were from women with clinically defined RIF (RIF). The 10 biopsies collected 
during this study were separated into two groups: the first group included six women 
who met collection criteria (Research), while the second group contained the remaining 
four women (Other), who did not meet the selection criteria due to having other fertility 







2.5 Endometrial sampling 
 
Part of the current IVF workup protocol at Fertility Associates New Zealand, is to perform 
a Pipelle biopsy of the functionalis layer of the endometrium. This sample is collected 
during the secretory phase of the menstrual cycle, the cycle before the IVF cycle. These 
are the samples used in this study. 
 
2.6 Cycle monitoring  
 
On the day of Pipelle sampling, a blood test was performed to test hormone levels 
including; LH, E2 and P4, to confirm the day of the menstrual cycle (Table 2.2). These 
results indicated that ovulation had occurred, and therefore that their hypothalamic 
pituitary gonadal (HPG) axis was functional in these women. This indicates that their 
point of failure to conceive through IVF may be related to the endometrium.  
A section of the sample was stored in formalin and sent to Southern Community 
Laboratory (Christchurch, New Zealand) for histological testing which allowed for a more 
precise estimate of the day of menstrual cycle (Table 2.2). 
The women in the Fertile and RIF cohorts had their biopsies collected during the early-
secretory, LH+2, phase of the menstrual cycle. The women in the Research and Other 
cohorts had their biopsies collected during a less accurate, later time point in the 










Table 2.2: Participant cycle dating using blood hormone levels and histological testing. 
Participant Cycle day by blood Cycle day by histology 
F1 LH+2 LH+2/P 
F2 LH+2 LH+2/P 
F3 LH+2 ESP/P 
F4 LH+2 ESP 
F5 LH+2 ESP 
RIF1 LH+2 ESP 
RIF2 LH+2 n/a 
RIF3 LH+2 ESP 
RIF4 LH+2 n/a 
RIF5 LH+2 n/a 
R1 SP SP 
R2 SP SP 
R3 SP SP (weak) 
R4 SP SP 
R5 SP SP 
R6 SP SP 
O1 N.O.  SP (weak) 
O2 SP n/a 
O3 SP SP 
O4 n/a n/a 
Note: F1-F5=Fertile cohort, RIF1-RIF5 = RIF cohort, R1-
R6=Research cohort, O1-O4=Other cohort, n/a = data not available, 
SP = secretory phase, ESP=early-secretory phase, P=proliferative 







2.7 Tissue processing  
 
The endometrial samples were divided into two portions. One portion was placed into 
formalin and was histologically assessed, while the second portion was stored at -80°C 
for laboratory testing. 
 
2.8 Methodology used  
 
An immunofluorescence protocol established by the LCPR group was used in this project. 
The Western blot protocol was modified for adaption to whole tissue samples. The 
quantitative polymerase chain reaction (qPCR) protocol was developed using the Gene 
Structure and Function Laboratory (GSFL; University of Otago, Christchurch) guidelines.  
 
2.9 Immunofluorescence  
 
Frozen sections were mounted onto a chuck using Optimal Cutting Temperature (OCT) 
compound (Tissue- Tek®) and cut at 8µm thickness using a Leica cryostat (CM1860 UV) 
set to -22°C. Nine frozen sections from the same participant were mounted onto 
individual Labserv Polysine microscope slides (Thermo Fisher Scientific, New Zealand. 
#LBSP4981); the coating on these slides assisted with adhesion of the tissue section to 
the slide. 
The sections on the slides were left to air dry at room temperature for up to an hour to 
further assist the section adhering to the slide. Slides were fixed in ice-cold Acetone for 
10 minutes. The acetone was drained off the slides and they were air dried for 15 minutes. 
A Dako pen (Sigma-Aldrich, Missouri, United States. #DAKS200230) was used to mark 
lines between sections to prevent antibody run-off, and allow three separate antibody 
tests, in triplicate, to be performed on a single slide. The slides were incubated in a humid 
chamber to prevent the sections from drying out during the labelling procedure. Blocking 
of non-specific binding sites was performed by adding 100 µL of 5% normal goat serum 
(NGS) (Invitrogen, California, United States) diluted in phosphate-buffered saline (PBS) 
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to each section. The slides were incubated on a shaker for 30 minutes at room 
temperature and then the NGS was drained off onto tissue paper. 100 µL of primary 
antibody, diluted 1:500 in 2.5% NGS in PBS was added to each section. PBS was used to 
dilute the reagents to minimise denaturing of the antibody. The sections were incubated 
with primary antibody (Table 2.1) 4°C overnight to minimize non-specific binding. 
Control slides were run in parallel, where 5% NGS in PBS was incubated in place of the 
primary antibody. 
The sections were drained of the primary antibody solution and were washed three times 
in cold PBS, for ten minutes each time on a vortex block with a stirrer to remove any 
remaining reagents that may have caused non-specific binding. Sections were drained 
onto tissue paper. Secondary antibody (Table 2.1) was then added: 100 µL of sheep anti-
mouse (SAM)-FITC in NGS (1:500 dilution in 2.5% NGS in PBS), or 100 µL of goat anti-
rabbit (GAR)-ATTO in NGS (1:500 dilution in 2.5% NGS in PBS) was added. Slides were 
incubated in the humid chamber covered with foil to prevent fading, for 60 minutes at 
37°C. The slides were drained, the washing steps were repeated and the sections were 
drained again onto tissue paper. The sections were then incubated with DAPI (4', 6-
diamidino-2-phenylindole), a blue fluorescent stain which binds to A-T rich regions in 
DNA of the cell nuclei. DAPI was diluted in PBS (1:500). Slides were incubated with the 
solution for 20 minutes at 37°C, drained, and then the washing steps were repeated and 
the sections drained for a final time onto tissue paper.  
Dako fluorescent mounting medium (#DAKS 302380), which contains anti-fading agent, 
was used to mount the sections while they were still wet and a coverslip was placed on 









2.9.1 Fluorescent microscopy 
 
A Zeiss microscope (Carl Zeiss Microscopy, Germany) was used to visualize the slides. 
Control slides were used as a control for autofluorescence. All slides were exposed for a 
standardized time of 44 milliseconds (ms) using the 200x magnification. DAPI, ATTO, and 
FITC staining was examined. A validated scoring method, discussed in section 3.1, was 
used to semi-quantify the intensity of the fluorescence, which correlates to the amount of 
protein in the sample.  
To control for individual analysis error, the slides were read in parallel by two observers, 
one having previous experience in this analysis. Having two analyses of the fluorescence 
allowed a more precise recording to be made. Ideally, individual analysis of the samples 
followed by blinded analysis by a second observer would have been optimal, however 
time constraints prevented this approach.  
Samples were analysed based on participants’ anonymized reference numbers, 
independent of their fertility identity, thus bias was minimized when scoring the 
fluorescence for each participant. 
 
2.9.2 Immunofluorescence results 
 
The staining intensity was reported as either strong, moderate, low, or absent, 3, 2, 1, 0 
respectively, and reflects the expression levels of the proteins. Staining intensities were 
recorded in each cell type: glandular epithelium, luminal epithelium, and the stroma. 
Immunolocalisation was also recorded. Staining patterns for all antibodies, except 
MKI67, were consistent throughout the sections where there was even dispersal of 






2.9.3 Statistical analysis of immunofluorescence  
 
A ranking procedure was conducted based on a weighted average as follows: the stromal 
component contributes to 80% of the total cells in the tissue based on observation, 
therefore had a 0.8 weight, while the luminal and glandular epithelium each had a 0.1 
weighting (0.8 Stoma+0.1 Glands+0.1 Luminal). Markers that had the greatest magnitude 
of difference between women with a fertile phenotype and RIF participants were 
considered to be of greatest importance. A one-way analysis of variance (ANOVA) 
followed by a Bonferroni t-test, or an unpaired t-test, was used to determine the proteins 
that had statistically significant changes in protein expression between groups. Standard 
error of the mean (SEM) was also calculated. 
  
2.10 Western blot  
 
Following the analysis of the immunofluorescence results, 15 markers were determined 
to have the greatest magnitude of difference in the endometrium between women who 
are fertile and women with RIF (Figure 3.2). Western blots were then performed to 
confirm and quantify differences in protein expression levels between fertile women and 
women with RIF. 
 
2.10.1 Tissue lysate preparation 
 
Chilled 1xPBS was used to wash off excess blood from the frozen endometrial tissue 
samples, and the weight of the sample was recorded. While maintaining the samples on 
ice, the endometrial tissue was cut into smaller pieces. Each sample was placed into 500 
μL of radioimmunoprecipitation assay (RIPA) buffer to homogenize the sample. The 
buffer contained phosphatase and protease inhibitor which prevented digestion of the 
samples. Samples were kept on ice to prevent denaturation, and were homogenized for 
30 minutes with intermittent vortexing. The sample was sonicated five times for 10 
seconds to ensure that the tissue was completely broken up. The samples were then 
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centrifuged at 9000 revolutions per minute (rpm) for 20 minutes to pellet cell debris. The 
supernatant was transferred to a sterile Eppendorf tube.  
To every 100 μL of lysate, 10 μL of 5% sample buffer plus 10 μL of 1 molar (M) 
dithiothreitol (DTT) was added just before use. This buffer has properties that assist with 
protein separation during sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE). The sample was vortexed, boiled for 10 minutes at 95°C, centrifuged again 
for 10 minutes, and then placed on ice until use. 
 
2.10.2 BCA protein assay  
 
A bicinchoninic acid assay (BCA assay) was performed for each endometrial lysate 
sample to ascertain the protein concentration in the sample against a standard curve 
using a Pierce™ BCA Protein Assay Kit (Thermo Scientific). This was completed by loading 
12.5 μL of a 1:20 dilution of each sample into a 96 well plate in duplicate, along with nine 
standard curve samples (blank through to 2000 nanomole per litre) also in duplicate. The 
working reagent was a 1:50 dilution of Reagent A: Reagent B; 200 μL of working reagent 
was added to each well. The plate was covered with foil and placed on a shaker for one 
minute and then incubated at 37°C for 30 minutes. After five minutes of cooling, the plate 
was read in a VIKTOR™3 Multilabel Counter (PerkinElmer) to quantify the absorbance of 
each sample against the standard curve.  
 
2.10.3 Polyacrylamide gels 
 
Gels were prepared using SDS-PAGE 10% separating solution and SDS-PAGE 7% stacking 
gel. 
Gels were placed into the electrophoresis container with running buffer. The left well was 
loaded with 2 µL of Precision Plus Protein™ Dual Color Standard ladder (catalogue #161-
0374) plus 1 µL of Magic Mark™ (Invitrogen- lot #1787635). The other wells were loaded 
with 50 micrograms (µg) of lysate (volume determined by BCA assay). From the Bio-Rad 
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3000Xi computer controlled electrophoresis power supply, 120 volts was applied to the 
gel until the dye had completely run out of the gel, which took approximately two hours.  
 
2.10.4 Transferring protein from gel to PVDF membrane  
 
A polyvinylidene difluoride (PVDF) membrane (Bio-Rad Immuno-Blot®) was used to 
transfer the proteins from the acrylamide gel. The membrane was soaked in 99% 
methanol (LabServ) for five minutes, rinsed, and then placed into transfer buffer along 
with paper and sponge for 15 minutes. The rinsed gel was placed on the PVDF membrane 
in the transfer holder, in between paper and sponges. The transfer holder was placed into 
the Bio-Rad Trans-Blot® Turbo transfer system for 60 minutes at 2.5 amps, at a maximum 
of 25 volts. Transfer success was determined using Coomasssie Brilliant Blue, where the 
solution was placed onto the acrylamide gel for 30 minutes on a shaker, and then washed 
with Coomassie destain. No blue stain after washing confirmed that the protein had 
transferred efficiently. If stained bands were present on the gel, it indicated that there 
was not 100% efficient transfer; in this case, transfer was repeated. 
The membrane was removed and placed into 5% skim-milk blocking solution in 5 
millilitres (mL) of TBS-T, on an orbital shaker for 60 minutes. The blocking solution was 
removed and 20 µL of primary antibody diluted in 5 mL blocking solution and 5 mL TBS-
T (1:500), was added to the membrane and incubated overnight at 4°C. Beta-actin (ACTB) 
was used as an internal reference. 
The PVDF membrane was washed in TBS-T buffer four times for 10 minutes each. 1.3 µL 
of secondary antibody, anti-mouse immunoglobulin G (IgG) horseradish peroxidase 
(HRP) or anti-rabbit IgG HRP, diluted in 6.5 mL TBS-T buffer and 6.5 mL blocking solution 
(1:1000), was added to the membrane and incubated for 90 minutes at room 
temperature. The membrane was then washed as previously described, with the addition 
of one final wash with milli-Q water.  
The membrane was transferred onto a transparent sheet with 1.5 mL of developing 
solution (Bio-Rad Clarity™ Western ECL Substrate- catalogue #170-5061) for 7 minutes. 
A UVTEC Geldoc machine (Uvitec Cambridge) using a set exposure time was used to 
visualize the intensity of the bands; this depended on which antibody was being detected.  
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2.10.5 Densitometry  
 
Using the UVTEC-band software, the density of the bands detected were calculated and 
represented as a ratio (target protein/calibrator sample: internal reference/calibrator 
sample). One-way ANOVA and un-paired t-tests were used to calculate significant 
differences between groups, based on the densitometry ratio. SEM was also calculated. 
 
2.11 Quantitative Polymerase Chain Reaction 
 
Quantitative PCR was used to quantify the amount of target complementary DNA (cDNA) 
within endometrial tissue samples using a fluorescent dye. Quantitative PCR was used to 
identify whether gene expression of the candidate markers was altered between women 
with different fertility phenotypes.  
  
2.11.1 Primer design 
 
Primers were designed using Roche Life Science’s Universal Probe Library (UPL) assay 
design canter (https://lifescience.roche.com/) and the University of California Santa Cruz 
(UCSC) Genome Browser (157) (Table 2.3). Target gene names were entered into the UPL 
search engine for Homo sapiens (humans) and appropriate sequences were selected. UPL 
provided a range of different primers based on the area of the gene that was to be 
amplified. Using the UCSC Genome Browser, the genes were also searched for alternative 
splicing transcript variants, to identify any regions of the genome that should not be 
amplified. This narrowed down the UPL search engine for appropriate primer pairs. 
Primers were designed to span intron/exon boundaries so that genomic DNA 
contamination could be ruled out later on, and tended to be toward the 3’ end of the 
amplicon. Appropriate primer pairs were chosen using the UPL system and then entered 
into the UCSC in silico PCR tool (https://genome.ucsc.edu/) to confirm that amplification 
would occur in the appropriate region, and to eliminate any primers that may amplify 
multiple areas in the genome. A Blast-like alignment tool (BLAT) search in UCSC (158) 
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was then conducted using the in silico PCR product which, was then referenced back to 
the gene of interest to ensure that the primers would amplify the correct region of the 
gene. Primers were designed complementary to the messenger RNA (mRNA) strand. 
Unfortunately, as UPL did not provide suitable primer pairs for some genes, for example 
did not cover intron/exon boundaries, this method was not applicable for all genes of 
interest, and further manual primer design would be required for these genes. Due to 
time constraints, these genes were excluded from qPCR analysis. In total, primer sets 
(forward and reverse sequences) were designed for ten genes. Three of were internal 
references, and these were selected based on previous reports that showed constitutive 
expression in endometrial tissue throughout the menstrual cycle.  
 
Table 2.3: Integrated DNA Technologies Primers designed using the UPL search engine. 































Note: UPL designs primers that have annealing temperatures around 60°C.  
 
All experiments were carried out in a PCR set-up lab free from any amplified DNA 
products. Standard anti-contamination conditions were used, including the use of double 




2.11.2 RNA extraction from tissue  
 
All equipment used for tissue processing was pre-cleaned with water, Trigene advance, 
ethanol (LabServ), and RNaseZap, and left to cool on dry ice for 20 minutes. Once the 
mortar and pestle had cooled, any excess ice that formed was wiped away, and the tissue 
sample was placed in the mortar. To help keep the samples cool, a small volume of liquid 
nitrogen was added. With a plastic cover over the pestle to prevent splash back and loss 
of tissue, the tissue was gently tapped to break up the sample and then stirred to form a 
white powder. The powder was transferred into a sterile Eppendorf tube, and was kept 
on dry ice.  
In the flow hood, 1 mL of Trizol® Reagent (Thermo Fisher Scientific) was added to the 
tissue and incubated at room temperature for 2 minutes. Following the incubation, 0.2 
mL of 99.8% chloroform (Sigma-Aldrich) was added to the tube and mixed for 15 seconds 
and then incubated again at room temperature for 2 minutes. The samples were 
centrifuged at 12,000 rpm at 4°C for 15 minutes. Three phases formed: DNA, protein, and 
RNA. There was approximately 600 µL of RNA, which was in the top aqueous phase.  
 
2.11.3 RNA purification 
 
Using the Norgen Biotek Corp RNA clean-up and concentration kit (Thorold, Canada), the 
RNA sample was purified using the following method: 70% ethanol was added to the 
sample at a 1:1 ratio of RNA to ethanol and vortexed for 10 seconds. A column was placed 
in a collection tube, 600 µL of the sample was applied to the column and centrifuged for 
1 minute at 6,000 rpm. After checking that the sample had gone completely through the 
column, the flow-through was discarded, the remaining RNA sample was applied to the 
column, and flow-through was again discarded. To the column 400 µL of wash solution 
was added, and was centrifuged for 1 minute at 6,000 rpm. Centrifugation was repeated 
if all of the wash solution did not pass through the column. The flow-through was 
discarded, and the washing step was repeated twice more, making a total of three column 
washes. In order to dry the resin in the column, the column was spun for 2 minutes and 
then the collection tube was discarded. The column was then placed into a sterile 1.7 mL 
37 
 
Eppendorf tube, 30 µL of RNA elution buffer was applied to the column, and it was left to 
stand at room temperature for 2 minutes. The sample was centrifuged for 1 minute at 
2,000 rpm and then 2 minutes at 8,000 rpm; the flow-through was collected and applied 
to the column again and centrifuged for 30 seconds at 14,000 rpm. The flow-through was 
again applied to the column, and previous centrifugation steps of elution buffer were 
repeated once more, and then the column was discarded.  
 
2.11.4 RNA quantification 
 
RNA yield was measured on a Nanodrop spectrophotometer (Thermo Fisher Scientific). 
The Nanodrop was blanked using milli-Q water, and then 2 µL of sample was added to 
the Nanodrop and an absorbance ratio of 260nm and 280nm (A260/280) was produced 
(ng/ µL). The A260 is representative of RNA quantity, while A280 is representative of 
contamination. This absorbance ratio is discussed in section 5.1.7.  
 
2.11.5 cDNA synthesis 
 
Reverse transcription (RT) was conducted with a pre-mix (Quanta bioscience XLT cDNA 
Super mix) using the following steps: in sterile strip tubes, 4 µL q script, RNA template 
(500ng), and a total of 16 µL of RNase free water (Invitrogen UltraPure™ Distilled Water), 
was added to make a reaction mix of 20 µL. The tubes were mixed and then spun down 
before being placed into the PCR machine (Thermo Fisher Scientific, Eppendorf™ 
Mastercycler™ PCR System – vapo.protect™). The samples were incubated for 10 minutes 
at 25°C, 30 minutes at 50°C and then five minutes at 85°C. Following PCR, 80 µL of milli-
Q water was added to the 20 µL of cDNA (1:5 dilution) and then the sample was stored at 





2.11.6 Quantitative PCR 
 
Quantitative PCR was carried out in a 384-well plate, using a Roche LightCycler® 480 II 
real-time PCR instrument (Roche Applied Science, Indianapolis, United States). Each 
reaction included 5 µL of target cDNA (diluted 1:5), which had been reversed transcribed 
from mRNA, 0.6 µL of 25 millimolar (mM) MgCl2 (Fisher Biotec, WA, Australia), 1 µL of 
TAQ-Ti DNA Polymerase 1x reaction buffer (Fisher Biotec), 0.1 µL of TAQ enzyme (Fisher 
Biotec), 1 µL of forward primer and 1 µL of reverse primer, 0.3 µL of SYTO9® green 
fluorescent nucleic acid stain (Invitrogen) diluted 1:100 from 5 mM stock solution, and 1 
µL of dNTPs 2 mM. Each PCR run on the LightCycler® contained a no-template control 
(NTC) (cDNA was replaced with water), experiments were carried out in triplicate, and a 
calibrator sample (pooled mRNA which was reverse transcribed to cDNA) was also used. 
A plastic adhesive was placed over the plate, the plate was briefly centrifuged, and then 
placed into the LightCycler® for quantitative analysis using a three-step PCR protocol 
(Figure 2.1).  
 
Figure 2.1: Quantitative PCR activation, annealing, and melt protocol on Roche LightCycler®.  
The qPCR protocol was as follows: polymerase activation at 95°C for 2 minutes, 40 PCR cycles including denaturation 
at 95°C for 10 seconds followed by annealing at 64°C for 10 seconds (red line). Fluorescence was measured at the end 
of each cycle (green dot). Lastly, the melting curve, which involved the temperature being increased to 95°C for 15 
seconds, reduced to 55°C for 15 seconds, and increased back to 95°C for a further 15 seconds, was also analysed. 
Fluorescence was again recorded (green line).  
 
2.11.7 Analysis of quantitative PCR 
 
There are different methods to look at the relative expression of genes based on the 
crossing point (Cp) or threshold, using fluorescence and the point that the fluorescence 
exceeds some threshold. Relative quantification was carried out using the 2^-ΔCp 
equation which calculated the relative difference between the target gene and the 
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internal reference. In this equation, 2 represents the efficiency, -ΔCp is the difference 
between the mean Cp of the target gene and mean Cp of the internal reference. Efficiency 
values varied depending on the gene of interest, mentioned in section 5.1.10, and 
therefore this value replaced 2. Standard deviations were calculated for the triplicate 
repeats per sample, per gene. In general if the standard deviation was < 0.5 then they 
were within range, while if there were outliers (>0.5), these were individually assessed, 
and, if necessary, removed from the analysis; this occurred in two cases.  
Box and Whisker plots were used to represent the normalised data (normalisation 
method described in section 5.2.3) using a median ΔCp for each group and the 



















3 Immunofluorescence Results 
 
Immunofluorescence is primarily a qualitative method for visualising molecules of 
interest and their distribution patterns throughout a tissue sample. This is achieved by 
using a fluorescent probe linked to an antibody raised against the molecule of interest. 
Preliminary work by the LCPR group used immunofluorescence to semi-quantitate the 
expression of specific markers in the endometrium, and identified down-regulation of 
some of these markers in women with clinically defined RIF in comparison to fertile 
women. This appears to be one of the first indications of differences in expression of 
protein markers within the endometrium during the early-secretory, non-receptive 
LH+2, phase of the menstrual cycle. In order to confirm these preliminary findings, 
immunofluorescence was used to visualise 25 candidate markers that were identified as 
being potentially important for endometrial development from the literature, as well as 
those identified by the LCPR group. This method was used as a general test to identify 
markers that may be significant, and that would subsequently be analysed using Western 
blot and qPCR techniques. Using immunofluorescence and fluorescent microscopy 
allowed for the detection of immunolocalisation of selected proteins, using a semi-
quantitative method for determining the relative expression level of proteins between 
samples.  
 
3.1 Semi-quantitative analysis of protein expression  
 
A number of previous studies have used semi-quantitative methods for analysing the 
amount of protein in tissue sections (159-161). The scoring method we used was based 
on recording the intensity of the staining, as mentioned in section 2.9.2. This method was 
adopted for this research in order to determine whether there were differences in protein 






3.2 Optimisation of Immunofluorescence protocol 
 
This protocol had been previously established by the LCPR group for analysis of 
endometrial samples. 
 
3.3 Cell types 
 
Cryo-sectioning of endometrial tissue allowed for the observation of the three main cell 
types: glandular epithelium, luminal epithelium, and stromal fibroblasts (Figure 3.1). 
During the menstrual cycle, the endometrial epithelium transitions to assist with 
proliferation, shedding, and regeneration of the endometrial lining. These three cell types 
were analysed separately when evaluating immunofluorescence results, as differences in 
protein expression patterns were observed.  
 
Figure 3.1: Cellular types.  
Endometrial tissue consists of the glandular epithelium (a), luminal epithelium (b), and the stromal compartment (c). 
Nuclei (stained with DAPI- blue) in the three regions were examined under 200x magnification. All three cell types 
undergo mitosis during the proliferative and early-secretory phases of the menstrual cycle. The luminal epithelium is 
able to transform from a state of non-receptivity during the majority of the cycle, to a state of receptivity, when the 
window of implantation is open, and is the first point of contact for a blastocyst during the implantation process. Scale 
bar = 200µm. 
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3.4 Magnitude of difference of protein expression between Fertile and RIF 
cohorts 
 
Immunofluorescence was used as the preliminary test to identify markers with 
significant differences between the fertile controls and the women with RIF. These 
markers were selected for further study using other methods. The magnitude of 
difference of the mean fluorescent score between the fertile women and women with RIF 
was calculated. Due to time constraints, the analysis was completed before all 
participants had been analysed. Candidate genes were narrowed down to 15 potentially 
important markers. These 15 markers became the testing frame for the remainder of the 
immunofluorescence analysis. Unpaired t-tests were used to identify the markers that 
showed statistically significant differences between the Fertile cohort and women with 
RIF, and were used for further analysis using Western blot and qPCR. After all 
immunofluorescence was completed, analyses including identifying magnitudes of 
difference (Figure 3.2), t-tests, and one-way ANOVA were repeated.  
 
 
Figure 3.2: Magnitude of difference between the fluorescent score results of women with a fertile phenotype and 
women with RIF.  
The differences between the mean fluorescent scores of the two cohorts ±SEM, which shows the markers that have the 
greatest differences between cohorts and therefore, represent potential markers for women with RIF. Error bars are 
















































3.5 Proteins up-regulated in the Fertile cohort  
 
Unpaired t-tests were used to analyse the mean scores for each group to identify 15 
candidate markers that showed the greatest differences in expression levels between 
cohorts. These results included a range of proliferation markers, PCNA, CCNA, MKI67, and 
SMAD3, that were significantly increased in the endometrium of fertile women (Figure 
3.3). The intensity of fluorescence in the RIF cohort was significantly less than in the 
Fertile cohort. 
 
Figure 3.3: Results of immunofluorescence of proteins down-regulated in women with RIF. 
(a) Immunofluorescence analysis, (b) and un-paired t-test of four proteins present in the endometrium, CCNA, PCNA, 
MKI67, SMAD3, in Fertile controls (n=5) and women with RIF (n=5). Fluorescent microscopy images visualised using 
200x magnification with a standardised exposure time of 44ms. Nuclei are stained with DAPI (blue), and proteins are 
stained with either GAR- ATTO (red) or SAM- FITC (green). Data shown are mean fluorescence scores ± SEM. Scale bar 





One-way ANOVA was completed for the 15 markers to identify any significant differences 
between the Fertile, RIF, Research, and Other cohorts (Figure 3.4). One-way ANOVA 
provided evidence that the Research and Other group have similar down-regulation of 




Figure 3.4: One-way ANOVA analysis of immunofluorescence results. 
Immunofluorescence scores between Fertile (n=5), RIF (n=5), Research (n=6), and Other (n=4) groups were averaged 
for (a) CCNA, (b) PCNA, and (c) MKI67. All three proteins were down-regulated in the Research and Other groups, in 
comparison to the Fertile cohort. Data shown are mean fluorescence scores ± SEM. *p<0.05, **p<0.01, ***p<0.001. 
 
3.6 Proteins down-regulated in the Fertile cohort 
 
IL1R1 is a marker in the endometrium that was identified, using immunofluorescence, to 
be down-regulated in the Fertile group in comparison to the RIF group (Figure 3.5). This 
was observed through greater fluorescence in the RIF cohort, and therefore increased 




Figure 3.5: Immunofluorescence results of proteins identifies as up-regulated in women with RIF.  
(a) Immunofluorescence analysis, and (b) un-paired t-test between Fertile and RIF groups for IL1R1. (c) One-way 
ANOVA of IL1R1 for Fertile (n=5), RIF (n=5), Research (n=6), and Other groups (n=4). Fluorescent microscopy images 
were visualised under 200x magnification with a standardised exposure time of 44ms. Nuclei are stained with DAPI 
(blue), and IL1R1 is stained with SAM-ATTO (red). When comparing the means of the Fertile and RIF groups, there is 
a statistically significant increase of IL1R1 in the RIF group. This difference is no longer significant when comparing 
the means of the Fertile, RIF, Research, and Other groups. Data shown are mean fluorescence scores ± SEM. Scale bar = 




3.7 Immunolocalisation of proliferation markers 
 
The luminal epithelium is the first point of contact that an invading blastocyst will make 
with the endometrium. Therefore, it is important that this compartment is prepared for 
implantation. An indication of this was observed, for example in CCNA. Increased protein 
expression was identified in the luminal epithelial cells in comparison to other cell types 




Figure 3.6: Results of immunofluorescence of luminal epithelial protein staining 200x magnification. 
(a) The luminal epithelial cells have stronger protein expression in comparison to the (b) stromal cells and (c) glandular 
epithelial cells, enforcing the idea that the luminal epithelium is preparing for implantation. Scale bar =200 µm. 
 
When scoring immunofluorescent staining in the endometrial samples, the typical 
staining patterns were observed for each marker (Figure 3.7). Different expression 
patterns indicated that these markers were localised in different regions of the 
endometrial cells, and suggested the possibility of different roles for particular proteins 




Figure 3.7: Results of immunofluorescence patterns of staining.  
Among the markers that were detected using immunofluorescence, different staining patterns were observed. These 
patterns were (a) punctate nuclear staining, where there was expression of the protein in localised regions nuclei of 
the cells called the nuclear poles, (b) diffuse nuclear staining, indicating expression occurring throughout the nucleus, 
and (c) diffuse cytoplasmic staining where the protein was expressed throughout all of the cytoplasm. Scale bar =200 
µm, arrows point to examples of staining pattern.  
 
3.8 MKI67 nuclear staining 
 
For all of the candidate markers tested, except MKI67, protein expression was observed 
in all three cell types. For example, PCNA expression was indicated by punctate nuclear 
fluorescence in every stromal, luminal and glandular cell. For MKI67, there appeared to 
be only a percentage of cells that expressed the protein (Figure 3.8). This could indicate 





Figure 3.8: Results of immunofluorescence analysis of endometrial stromal cells that showed varying expression 
of MKI67.  
When expression of MKI67 actively occurs in the nuclei of cells, immunofluorescence detected this as a pink stain where 
the red GAR-ATTO probe for MKI67 stained over the blue DAPI nuclei stain, creating a pink signal. (a) Fluorescence 
signal is increased in fertile participants and decreased in RIF participants, when compared under 200x magnification. 
This finding was confirmed with (b) an unpaired t-test to compare the percentage of cells that had nuclei staining in 
the stroma between fertile women (n=5) and women with RIF (n=5). Data shown are mean immunofluorescent scores 




3.9 Conclusions from immunofluorescence 
 
Primary testing of candidate markers of endometrial proliferation has indicated 
alterations in protein expression between women who can achieve successful 
implantation and women who have RIF. The proliferation markers PCNA, SMAD3, CCNA, 
and MKI67 appear to be important for endometrial function, as women with RIF appear 
to have down-regulation of these proteins during the pre-receptive, secretory phase, 
which is an important time for endometrial preparation prior to the opening of the WOI. 
PCNA, CCNA, and MKI67 were also significantly down-regulated in the Research and 
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Other groups, which supports the hypothesis that the fertility phenotypes of these 
women also relate endometrial proliferation. Conversely, IL1R1 expression appeared to 
be poorly expressed in the Fertile group, while the RIF group had significantly increased 
expression. This suggested that overexpression of certain endometrial markers may also 
have negative effects on implantation success. 
Protein expression patterns have been successfully identified for all of the 25 markers in 
a well-defined Fertile group of women who have achieved implantation and a group of 
women with RIF. This allowed us to observe where the protein was being expressed at a 
cellular level. Increased expression in the luminal epithelium of the proliferation markers 
studied underlines the potential importance of these proteins for adequate implantation 
preparation.  
 
3.10 Limitations of the immunofluorescence procedure 
 
This method was suitable for observing a range of markers relatively efficiently, noting 
staining intensity and localisation within the cells of the endometrium. This method is 
frequently used and reported for semi-quantifying the amount of target molecules 
present, and the limitations of the method are understood and accepted. To semi-quantify 
the intensity of staining, the principle that the more target antigen present, the more 
fluorophores would bind, leading to greater fluorescent signal is amplification, was 
applied. By assigning a number to different fluorescent intensity strengths, quantitative 
analysis was performed to look for differences between the test groups. As this method 
was completely based on observer interpretation, it could not be bias free. To overcome 
interpreter bias, two observers interpreted the results, and the average of the two 
findings was recorded.  
A standardised exposure time of 44 ms was used for all fluorescent readings, and 
therefore the mercury vapour lamp quality was important. The original fluorescent 
readings had been recorded when the lamp had exceeded the manufacturer’s 
recommendation of 200 user hours. Initially, the Fertile and RIF cohort samples were 
read with a mercury lamp that was outside accepted guidelines. This resulted in 
repeating a large number of samples, using a new bulb.  
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Reading slides in replicate was also performed, particularly for negative results. Issues 
with antibody dispersal throughout the tissue was detected in some samples. Results 
were confirmed by repeat testing or repeat reading in different areas or sections of the 
slide.  
Immunofluorescence has known issues of non-specific binding and autofluorescence. 
Non-specific binding can occur due to the primary antibody forming ionic bonds, and, 
therefore, binding to incorrect target molecules. This was minimised by blocking with 
NGS. Autofluorescence is the natural light emission that a particular molecule can 
produce, and therefore it was important to run negative controls using NGS in PBS instead 
of primary antibody to ensure that fluorescence associated with non-specific binding was 



















4 Western Blot Analysis Results 
 
Western blot analysis is a sensitive technique that allows detection of proteins of interest 
by separating the proteins based on their size, followed by visualization using specific 
antibodies. Preliminary analysis using immunofluorescence detected a number of 
proteins showing different levels of expression between the different groups of 
participants. We chose the 15 markers with the greatest magnitude of difference between 
the Fertile and RIF cohorts to analyse using Western blot. Western blot analysis allows 
quantification of the expression of these markers within the tissue.  
 
4.1 Optimisation of protocol 
 
The Western blot method is regularly performed by the LCPR group, and their established 
protocol provided the initial basis for this study. Most of the markers to be tested had not 
been previously used for Western blot in this laboratory. Also, only cell lysates had 
previously been used, and so the protocol required further optimisation for use with 
whole tissue lysates. 
  
4.1.1 Primary and secondary antibodies 
 
Primary antibodies that were used for the immunofluorescence analysis, supplied by 
Santa Cruz, were also used for Western blot analysis (Table 2.1). Secondary antibodies 
used were anti-mouse or anti-rabbit HRP-conjugated antibodies that have been 
previously validated for protein analysis in the laboratory (Table 2.1). For confirmation 
of the reactivity of the antibodies, a dot blot test was performed as follows.  
In the center of a piece of PVDF membrane, 2 µL of sample was loaded and left to dry 
before 1 µL of primary antibody was added and again left to dry. Following this, 0.5 µL of 
secondary antibody was added and left under the hood with the fan operating for 30 
minutes. Once dried, 2 µL of developing solution was loaded onto the membrane and left 
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to dry. The reaction was then visualised in order to confirm whether the protein was 
staining (Figure 4.1). This test only validates antibody reactivity and this method is not 
used to quantify the presence of proteins; nor can this dot blot test exclude non-specific 
binding.  
 
Figure 4.1: Dot blot test to confirm antibodies were reactive.  
Arrows point towards the center circle of protein staining, which confirms the reactivity of the antibody, while the 




4.1.2 SDS-PAGE running 
 
In general, the concept of allowing the proteins to run through the gel until the sample or 
loading dye had completely run out, was adhered to. These proteins were run on a 10% 
acrylamide separating gel. There was an exception for MKI67, which had a molecular 
weight of 395 kilodalton (kDa), and therefore had to be run for a longer amount of time 
until the 75 kDa mark on the 250 kDa ladder was at the bottom of the gel. MKI67 was also 
run on different percentage gels in order to allow this heavy protein to migrate through 
the gel (Figure 4.2). A 7.5% acrylamide separating gel was trialled, however this was still 
too concentrated for MKI67. Subsequently, the percentage of acrylamide was decreased 
to a 5% separating gel. Unfortunately, this was still not adequate, as clear bands at the 






Figure 4.2: Different percentage acrylamide gels used to detect the large molecular weight protein, MKI67.  
Acrylamide concentrations were altered to increase SDS-PAGE success for running MKI67. Arrows point to 
separating/stacking gel junction. Using a 10% acrylamide gel showed no evidence of this large weight protein 
migrating within the separating gel. Reducing the gel to 7.5% acrylamide shows that the protein may have travelled 
into the separating gel, however there are no specific bands visible, and protein appears to still be within the stacking 
gel. A 5% acrylamide gel demonstrates more concentrated protein bands appearing within the separating gel, however 
this was still not sufficient to estimate MKI67 density.  
 
 
4.1.3 Protein transfer to PVDF membrane 
 
Protein transfer from the acrylamide gel to the PVDF membrane was performed using a 
semi-wet turbo transfer Bio-Rad machine. The laboratory protocol called for a 15 minute 
transfer time at 25 volts in this apparatus. However, when Western blots were failing to 
work at this transfer time, staining for protein transfer success was attempted (Figure 
4.3). After transferring for 15 minutes, Ponceau S stain was added to the membrane and 
Coomassie Brilliant Blue stain was added to the gel. There was no Ponceau S protein 
staining which indicated that the protein had not transferred onto the membrane from 
the gel. After washing the Coomassie stain off, bands appeared which confirmed that the 
protein was still in the gel. To overcome this, the transfer time was increased to 30 
minutes at 25 volts and staining was repeated, however there was still high molecular 
weight protein staining in the gel. Finally, a 1 hour transfer time was used, and Coomassie 




Figure 4.3: Coomassie Brilliant Blue and Ponceau S staining for transfer efficiency from gel to membrane.  
Coomassie Brilliant Blue stained the protein within the polyacrylamide gel, while Ponceau S stained proteins 
transferred onto the PVDF membrane. At a 15 minute transfer time, protein staining was present above the 50 kDa 
mark in the gel, while there was no protein transfer onto the PVDF membrane in the same molecular weight range. 
After a 30 minute transfer time there was protein staining at 100 kDa, and very little other protein present, which 
indicated that the increased transfer time was more efficient. At a 60 minute transfer time there was no protein 
detected in the gel which indicated that this transfer time was efficient. 
 
 
4.1.4 Blocking reagents 
 
Following current laboratory protocol, the blocking solution used for rabbit antibodies 
was 5% skim milk, while the blocking solution for mouse antibodies was 1% BSA. This 
established system was not adequate for some antibodies used in this study, and thus 
experimentation with different blocking solutions and concentrations of solutions was 
required. An example of an antibody that required these blocking conditions to be 




Figure 4.4: Altering blocking solution for anti-PCNA antibody.  
Anti-PCNA is a mouse antibody, and the laboratory protocol suggested that this antibody should be blocked with 1% 
BSA. However, these conditions resulted in non-specific background staining. Skim milk was then used, which was 
sufficient for reducing background staining for a clearer blot. 
 
4.1.5 Antibody incubation conditions 
 
Primary antibodies were incubated at 4°C overnight as per laboratory protocol. Different 
incubation times, overnight, 2 hours, and 1 hour, were tested. Different temperatures 
were also trialled, including 4°C, room temperature, and 37°C. The majority of primary 
antibodies were incubated overnight at 4°C, except for Tryptophan 5-Monooxygenase 
Activation Protein Zeta (YWHAZ) which was incubated at room temperature, overnight 
(Figure 4.5), and ACTB which was incubated at room temperature for 1 hour. All 
secondary antibodies were incubated at room temperature for 90 minutes, except for 
ACTB which was only incubated for 30 minutes.  
 
 
Figure 4.5: The incubation conditions for primary antibody YWHAZ.  
YWHAZ showed no background staining at 4°C overnight, however the clarity of the bands was poor. When incubating 











4.1.6 Samples for optimisation  
 
Western blot optimisation was completed using a range of samples (not shown). 
Originally, a single sample from a participant with a suspected fertile phenotype was 
used, however, there was minimal detection of any markers. This could have been a result 
of other protocol issues, including protein transfer failure. Subsequently, patient notes 
revealed that this participant had an infertile phenotype. It was hypothesised that 
infertile phenotypes would have reduced levels of the proteins of interest, and so this 
sample was not ideal to use for optimisation. Minimal protein detection was also 
observed when analysing an additional woman with a fertile phenotype; however, it was 
later identified that this participant’s sample was collected at the later LH+7 phase. 
Preliminary work identified altered protein expression of the candidate proliferation 
markers between the LH+2 and LH+7 phases. This could explain the reduced detection of 
proteins at the LH+7 phase. For satisfactory optimisation, a sample from the LH+2 phase 
should have been selected. Ovarian cancer cell lysates, from OVCAR4, OVCAR5, and 
SKOV3, were used as proxy samples, or positive controls, to overcome the issues with 
attempting to optimise using infertile women or samples from different phases. These 
samples are known to have high expression of markers such as EGFR. Western blots were 
run on cell lysates using the existing protocol to detect EGFR, in order to confirm whether 
issues with protein detection were due to the protocol or the use of endometrial tissue 
lysates. These cell lysates were run in parallel with endometrial tissue lysates. Western 
blot detected EGFR in the cell lysate, however there was poor detection in the tissue 
lysate. This suggested that the failure of protein detection was likely to be due to sample 
issues. A sample from a fertile women at the LH+2 phase was then run under the existing 
protocol conditions, and protein was finally detected. All collected participant samples 







4.1.7 Sample buffer 
 
As the blots were not of high quality, the efficacy of the sample buffer used was 
considered. In the LCPR group, DTT is not used in the sample buffer as part of the Western 
blot protocol. The cell lysate analysed had high concentration of the proteins of interest, 
with minimal non-specific material present. However, the endometrial tissue lysate was 
produced from whole tissue, and had non-specific material, along with potentially low 
expression of the target proteins. It was proposed that DTT was required for optimal 
Western blotting using the tissue lysates. Using the tissue lysate in the sample buffer, DTT 
was added at a volume of 10% of sample volume and the sample was boiled. The same 
protocol conditions were used as previously, using the new tissue lysate, and clear 
protein bands were detected. It was concluded that DTT is important for tissue lysis, as it 
assists with unfolding the proteins for better separation through the acrylamide gel 
(Figure 4.6).  
 
 
Figure 4.6: Western Blot demonstrating the addition of DTT to the sample buffer for detection of the protein 
MCM2. 
DTT, which is important for separating proteins during SDS-PAGE, was not originally used in the sample buffer. When 
DTT was not present, protein bands are very unclear. When DTT was present, clear protein bands were detected.  
 
4.2 Western Blot results 
 
In the time-frame of this study, a total of four target proteins, PCNA, CCNA, MCM2, and 






4.2.1 The use of YWHAZ and ACTB as an internal control 
 
YWHAZ had been reported by the LCPR group as a suitable internal reference for 
analysing endometrial samples, as YWHAZ was found to be consistently expressed in 
another cohort of fertile women (71). However in our study, expression varied between 
women with different fertility phenotypes, and therefore it was not suitable for use as a 
reference. ACTB was then trialled, and it was confirmed to have consistent expression 
between participants, and therefore was a suitable loading control.  
A significant reduction of YWHAZ was detected in the RIF group when comparing protein 
expression, relative to ACTB (Figure 4.7). This finding indicates that YWHAZ is 
differentially regulated between women with different fertility phenotypes, and is likely 
to be responding in its role in the cell cycle pathway, which results in proliferation.  
 
 
Figure 4.7: Relative expression of YWHAZ to ACTB and densitometry.  
(a) Western blot analysis, (b) one-way ANOVA, and (c) unpaired t-test of ratio of YWHAZ to ACTB expression. There is 
a statistically significant reduction in YWHAZ expression in the RIF group (n=5) in comparison to the Fertile group 
(n=5). While the Research (n=6) and Other (n=4) groups do not have any significant changes in YWHAZ expression. 






4.2.2 Non-significant results 
 
Western blot analysis suggested that there was no statistical difference of MCM2 
expression between the Fertile group, and other three groups (RIF, Research, and Other) 
(Figure 4.8). This result reflected the results seen using immunofluorescence. MCM2 is a 
marker of proliferation that features in the cell cycle. Although there is no significant 
difference between groups, a trend suggests that there is a reduction of this proliferation 
marker in the three test groups (RIF, Research, and Other).  
 
 
Figure 4.8: Densitometry analysis of MCM2 expression in endometrial samples between groups.  
(a) Western blot analysis, (b) one-way ANOVA, and (c) un-paired t-test of MCM2 expression in ratio to ACTB internal 
reference. There is a no statistically significant differences between groups, however there appears to be a trend 
towards reduced MCM2 expression in the three infertile groups, RIF (n=5), Research (n=5), and Other (n=4), in 







Immunofluorescence results detected a significant reduction of CCNA protein expression 
throughout endometrial tissue in RIF and Research cohorts, in comparison to the Fertile 
cohort. CCNA was also tested using Western blot protein detection, although no 
significant difference was detected between the four cohorts (Figure 4.9). An apparent 
trend towards decreased levels of CCNA was detected in the three infertile groups (RIF, 
Research, and Other).  
 
Figure 4.9: Densitometry analysis of CCNA expression in endometrial samples between test groups.  
(a) Western blot analysis, (b) one-way ANOVA, and (c) unpaired t-test of CCNA to ACTB expression. There is no 
statistically significant difference between groups, however there is an apparent trend towards reduced CCNA in the 
RIF (n=5), Research (n=6), and Other (n=4) groups, in comparison to the Fertile group (n=5). Data shown are mean 
densitometry ratios ± SEM. 
 
4.2.3 Significant results 
 
Immunofluorescence detected a statistically significant reduction of PCNA expression in 
the RIF group in comparison to the Fertile group. This difference was confirmed using 
Western blot (Figure 4.10), and indicates its importance as a proliferation marker in the 
endometrium. Trends for PCNA suggest a reduction of the proliferation marker in the 





Figure 4.10: Densitometry analysis of PCNA expression in endometrial samples between test groups.  
(a) Western blot analysis, (b) one-way ANOVA, and (c) unpaired t-test of ratio of PCNA to ACTB. There is a statistically 
significant reduction of PCNA in the RIF group (n=5) in comparison with the Fertile group (n=5). This trend was also 
observed in the Research (n=6) and Other (n=4) groups. Data shown are mean densitometry ratios ± SEM, *p<0.05. 
 
Densitometry of Western blots for PGR showed a statistically significant reduction of the 
protein in the RIF group compared to the Fertile group (Figure 4.11), and could therefore 
represent a promising marker of proliferation. The Research and Other groups did not 




Figure 4.11: Densitometry analysis of PGR expression in endometrial samples between test groups. 
Western blot analysis, (b) one-way ANOVA, and (c) un-paired t-test of the ratio of PGR to ACTB. PGR has two isoforms, 
A and B, which are observed at 81 kDa and 116 kDa respectively. There is a statistically significant reduction of PGR in 




4.3 Western blot summary 
 
Overall, Western blot analysis confirmed the findings from immunofluorescence analysis. 
Results from immunofluorescence and Western blot indicated reduced PCNA protein 
expression in the RIF cohort in comparison to the Fertile cohort. Immunofluorescence 
detected a significant reduction in CCNA expression in the RIF cohort, but this was not 
confirmed with Western blot. However, there was a trend towards reduced expression. 
Western blot analysis also detected a significant reduction of PGR in the RIF group, which 
was not detected through immunofluorescence, suggesting that a more precise estimate 
of the amount of PGR protein present in the samples was possible using Western blot. 
PGR was not significantly reduced in the Research and Other cohorts which may indicate 
that the women in these two groups do not have fertility phenotypes associated with this 
receptor, while the women with RIF do. YWHAZ was not tested using 
immunofluorescence, but was detected using Western blot as significantly reduced in the 
RIF group. This was consistent with its role in the cell cycle, and, potentially, in 
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endometrial proliferation. No significant differences in MCM2 expression were seen 
between groups using both Western blot and immunofluorescence. Although, Western 
blot analysis suggested a trend towards reduced MCM2 expression in the infertile 
cohorts, further analysis with larger sample sizes is required to confirm the trend. As 
CCNA and MCM2 were the two protein markers that had no significant differences 
between the Fertile and RIF cohorts, it suggests, that at this stage, these two markers are 
probably not important for determining proliferation adequacy.  
 
4.4 Limitations of Western blot procedure.  
 
Western blot is a more quantitative antibody-based method for identifying proteins of 
interest than immunofluorescence. It was easier to minimise non-specific binding of 
antibodies using Western blot, in comparison to immunofluorescence, as non-specific 
binding tended to appear at different molecular weights. Accordingly, it is likely that 
protein detection at the target molecular weight is more likely to be the target protein.  
Western blot required proteins to be transferred from a gel to a membrane. Lower 
molecular weight proteins were transferred easily, while higher molecular weight 
proteins were more difficult to transfer. This problem was encountered when 
transferring the protein MKI67, which has a molecular weight of 395 kDa. This led to 
MKI67 not being detected during the time-frame of this project, and was therefore 
excluded from Western blot analysis. 
Unlike immunofluorescence, Western blot analysis did not allow for protein detection in 
individual cell types. Whole tissue was used to make the tissue lysate, which meant that 
all cell types were included. Therefore, it was impossible to isolate the expression of the 
protein for each cell type. In immunofluorescence, each of the three cell types could be 
quantified, and a subsequent weighted score for each section calculated based on the 
proportion of the cell type in the overall tissue. This could explain some of the differences 







5 Quantitative Polymerase Chain Reaction Results 
 
Quantitative PCR was used to measure gene expression as another method to validate 
immunofluorescence and Western blot protein analyses.  
 
Quantitative PCR is a very sensitive technique that can quantitate gene expression, even 
using small sections of tissue and small amounts of RNA. There are two approaches to 
detect the level of gene expression: TaqMan probes or fluorescent dye-based methods 
including SYBR-green or SYTO9. TaqMan probes use a specific fluorescent probe that 
fluoresces when amplification occurs. Alternatively, for the dye-based methods, the dye 
fluoresces when bound to any double-stranded DNA. SYTO9 was used for this study. 
Quantitative PCR can be used to calculate a relative difference in specific gene expression 
between different tissues.  
 
5.1 Quantitative PCR optimisation  
 
Quantitative PCR had not been previously used in this laboratory of gene expression 
analysis of endometrial samples. Using the Minimum Information of Quantitative Real-
Time PCR Experiment (MIQE) guidelines (162), a qPCR protocol was established for use 
with endometrial tissue.  
 
5.1.1 Primer design  
 
Primer pairs were designed using the Roche UPL-Design Center, as mentioned in section 
2.11.1. MIQE guidelines suggest that more than one internal reference should be used for 
qPCR. To identify appropriate internal references, a literature search was carried out to 
identify genes that are constitutively expressed in endometrial tissue (163-166). Primers 
were designed for three potential internal references: ACTB, YWHAZ, and CYC1, and six 





5.1.2 cDNA synthesis using lymphoblastoid cell line RNA 
 
Lymphoblastoid cell line (LCL) RNA was initially used to validate the primers designed. 
The LCL RNA was reverse transcribed using Superscript® III Reverse Transcriptase kit 
(Invitrogen, ThermoFisher) which allowed for plus superscript (+RT) and minus 
superscript (- RT) reactions. Having a –RT reaction controls for inadvertent amplification 
of any genomic DNA contamination. Reactions were set up in a strip tube on ice and 
contained the following: 1 µL of OligodT primer, 1 µL of 10 mM dNTP mix, 
Diethylpyrocarbonate (DEPC) treated water, and 1 µg/µL of mRNA template, in a 10 µL 
reaction volume for + RT, and a 12 µL volume for – RT. Lids were put on the strip tubes, 
which were then placed into the Eppendorf Mastercycler Thermal cycler (GlobalScience, 
Germany) and heated to 65°C for 5 minutes and then placed back on ice. After 5 minutes 
on ice, 4 µL of 5x First Strand Buffer, 1 µL of 0.1 M DTT, and1 µL of RNase OUT was added 
to each reaction. Additionally, 2 µL of Superscript® III was added to the +RT reaction. The 
strip tubes were reloaded into the thermal cycler and incubated at 50°C for 60 minutes, 
and then inactivated by heating to 70°C for 15 minutes. To remove complementary RNA, 
1 µL of RNase H was added and then incubated at 37°C for 20 minutes. The cDNA sample 
was diluted1:5 by adding 80 µL of milli-Q water to each 20 µL reaction.  
Primer testing was conducted for each primer pair using a +RT and –RT LCL cDNA in a 
10 µL reaction volume. A sterile 48-well plate, designed for the Eco™ Illumina real-time 
PCR system, was used and the following was added to each well: 1 µL of 0.5 nM forward 
primer and 1 µL of 0.5nM reverse primer, 0.6 µL of 1.5mM MgCl2, 1 µL of cDNA template 
(diluted 1:5), 1 µL of pCR buffer, 1 µL of dNTP, 0.1 µL of TAQ, 0.3 µL of SYTO-9 fluorescent 
dye diluted 1:100, and 4 µL of milli-Q water, per reaction. The plate was centrifuged and 
then run in an Eco™ Illumina real-time PCR system. PCR steps were completed, as per the 
qPCR protocol in methods section 2.11.6, except the annealing temperature was set at 
60°C. 
Any reaction with amplification detected by the real-time PCR machine was then run on 
the MultiNA (Shimadzu), an automated, digital electrophoresis system, to ensure that 
amplicons were of the correct size. This was completed as follows: the 10 µL reaction mix 
from each of the wells in the 48-well plate were transferred into sterile strip tubes and 
placed into the MultiNA machine. The MultiNA requires one large tube containing buffer 
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(volume required was detected by machine) and dye (10% of buffer volume), a medium 
1.6mL Eppendorf tube containing marker (volume required detected by machine), and a 
small 0.6mL Eppendorf tube containing either 7 µL of 25 base-pair ladder for a 2-chip 
run, or 5 µL for a single-chip run. An electronic output of the PCR products against the 25 
base-pair ladder was produced.  
Of the primers that produced amplification, EGFR, CYC1, and PCNA produced the correct 
sized amplicons, while all other reactions either had no amplification or non-specific 
amplification (not shown).  
The primer failures could have been due to the genes not being expressed in the LCL 
sample, incorrect primer design, or incorrect annealing temperatures.  
 
5.1.3 Gene amplification using cDNA synthesised from two fertile participants 
 
Using a one-step reverse transcription kit, as described in section 2.11.5, mRNA from two 
fertile participants was reverse transcribed. This one-step kit had Superscript included 
in the master mix, and therefore it was not possible to run +RT and –RT reactions. The 
PCR reactions that were carried out for the LCL sample were repeated for these samples.  
Amplification was detected using each primer pair, and all samples were subsequently 
run on the MultiNA (Figure 5.1). Of the ten primer pairs tested, two (CDKN2A and TGFα) 
did not display the right sized amplicon, and consequently were excluded from further 
analysis. The other six primer pairs had the correct sized amplicon, and two had the 





Figure 5.1: All primer pair reactions run were run on the MultiNA, using RNA from two fertile participants, to 
detect amplicon sizes.  
Aplicon sizes for CDKN2A and TGFα were of incorrect sizes. YWHAZ and MKI67 presented with the correct size amplicon 
(blue boxes), but also had non-specific amplicon detection in both participants samples. EGFR, CYC1, PGR, MKI67 and 
MCM2 presented with the corect sized amplicon (red boxes) and none to minimal non-specific bands. 
 
 
5.1.4 Dilution series 
 
In order to establish that the concentration of cDNA used was appropriate for the 
reactions, and to test the efficiency of the primers, the remaining eight primer pairs were 
run in a dilution series. The dilution series contained the following dilutions of cDNA: NTC 
(0), 1 µL of a 1:100 dilution, 1 µL of a 1:10 dilution, and 1 µL of a 1:5 dilution. The reactions 
were then run on the MultiNA to detect preferential production of the amplicon (Figure 
5.2). PGR, PCNA, ACTB, and MKI67 showed the correct size amplicon at a 1:5 dilution, and 
none/minimal non- specific amplification. MCM2, CYC1, and EGFR had the correct size 
amplicon but showed background amplification, and consequently needed further 
optimisation. YWHAZ showed only non-specific signals, and so was excluded from any 




Figure 5.2: Dilution Series for eight primer pairs to test for primer efficiency.  
Four different dilutions were tested for the remaining eight primer pairs. This was completed to establish a 
concentration of cDNA that produces optimal bands for the amplicon of interest, which would ideally produce only the 




5.1.5 Temperature gradient 
 
As MCM2, EGFR, and, CYC1 had non-specific bands to be removed, they were tested using 
one of the fertile participants’ cDNA in a thermal cycler using a temperature gradient. The 
gradient started at an annealing temperature of 60°C, which is the temperature that UPL 
recommended for the primers, and also at 62°C, 64°C, and 66°C. NTC’s were also run in 
parallel. This temperature gradient should have been carried out for all primer pairs, but 
due to limited time, the primers that were not working efficiently at 60°C were 
prioritised. The reactions were run again on the MultiNA (Figure 5.3). This detected only 
non-specific amplicons for all three water sample primers sets, and at 66°C, no products 
were detected for any gene. CYC1 showed one clear band at 60°C indicating that this 
temperature was the most efficient for this primer set, while other temperatures started 
showing other non-specific products at higher annealing temperatures. MCM2 and ACTB 
showed no non-specific products in the 60 to 64°C annealing range, while at 66°C, non-
specific bands started to appear for MCM2, and no bands were detected for ACTB. To get 
a balance between reducing non-specific bands in the water controls, and increasing the 
clarity of the target bands in the template samples, an annealing temperature that 
considered both of these factors needed to be chosen; 64°C appeared to be the optimal 
temperature for all three primer pairs, as it showed the least product in the NTCs, while 




Figure 5.3: Annealing temperature gradient for CYC1, MCM2, and ACTB.  
Four different annealing temperatures, 60°C, 62°C, 64°C, and 66°C, were tested for the three genes in order to confirm 
the best temperature for primer annealing, without increasing background noise. 64°C appeared to be the optimal 
temperature for achieving this.  
 
5.1.6 Running all primer pairs at 64°C 
  
All seven primer pairs were run on the LightCycler® (Roche), at 64°C with NTC (not 
shown). On the LightCycler®, the melt-curves showed that MKI67 had primer dimers 
(Figure 5.4), while all other six primers had a single melt-curve peak. The amplification 
plot for MKI67 was also concerning as the amplification in the template and NTC samples 
were occurring during the same cycle. Primer dimers form when the forward and reverse 




Figure 5.4: Melting peaks and melting curves for MKI67 at 64°C.  
When running the remaining seven primer pairs at 64°C on the light cycle, MKI67 had concerning activity when 
analyzing melt information. (a) The melting peaks showed two significant peaks at different temperatures which 
indicate primer dimers, or non-specific amplification, occurring. (b) The melting curves showed two different melting 




5.1.7 RNA extraction/ RNA quality on MultiNA 
 
Using high quality RNA for qPCR is essential. To ensure that the RNA extracted from the 
endometrial samples was of good quality, an A260/280 ratio was produced, in addition 
to running RNA on the MultiNA (Figure 5.5).  
RNA was tested on the Nanodrop spectrophotometer (Section 2.11.4), and the A260/280 
ratio was determined for each sample to establish the quality of RNA. The normal range 
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of high quality RNA is between 1.8 and 2 ng/µL, where 2 ng/µL is considered pure RNA. 
The RNA yields of samples in this study had ratios between 1.83 and 2.1, which indicated 
high quality RNA yields, with minimal degraded RNA. 
Testing RNA on the MultiNA required a different protocol to the post-PCR test, and was 
carried out as follows: in the large tube was 790 µL of separation buffer, 10 µL of diluted 
SYBR green 2 dye (diluted 1:100 with RNase water) and 200 µL of Formamide. In the 
small strip tube was 7.5 µL of diluted RNA ladder (1:6) and 7.5 µL of marker solution. 
Reactions were set up in strip tubes containing 1 µL of RNA, regardless of the 
concentration, 3.5 µL of RNase free water, and 4.5 µL of marker solution. A water blank 
was run in parallel. Immediately before the analysis, the samples were heated to 65°C for 
5 minutes and cooled to 4°C for 5 minutes to denature the single stranded mRNA. The 
MultiNA runs showed that each of the samples had 28S and 18S bands (Figure 5.5). Some 
bands were fainter than others, but this was probably due to variable concentrations of 
input RNA.  
 
Figure 5.5: RNA Quality check for 28S and 18S bands. 
The majority of RNA samples presented with clear 18S and 28S bands, with minimal degraded RNA. Samples that 
produced weak signals at the 18S and 28S levels were from low concentrated RNA samples which explains why they 
had less recognisable bands. 
  
 
5.1.8 cDNA synthesis of pooled RNA 
 
Using pooled RNA from all endometrial samples, reverse transcription was carried out. 
Pooled RNA was used to minimise the use of each participants’ RNA. The seven remaining 
genes were checked on the LightCycler® at 64°C. Non-specific amplification was 
occurring in the –RT controls, and so the PCR was repeated at 62°C in triplicate. This 





5.1.9 Sequencing of PCR products 
 
More cDNA was made from the pooled RNA (500 ng/µL) using the one-step kit that was 
to be used for the final procedure. To further ensure that the products amplified were the 
correct amplicons, a reaction for each primer pair was set up so that the products could 
be sequenced. The reactions were set up as described in section 5.1.2 using the pooled 
cDNA, except SYTO9 was not included. PCR was carried out with an annealing 
temperature of 62°C. The reactions were again run on the MultiNA to determine the size 
of any amplification products (Figure 5.6).  
After running on the MultiNA, the samples were diluted 1:3 with milli-Q water. 1 µL of 
this dilution was added to a 10 µL sequencing reaction (Applied Biosystems Big Dye 
Terminator, or BDT, version 3.1). This included 1 µL of 5 µM primer, 2 µL of 5x BDT 
sequencing buffer, and 0.5 µL of BDT terminator. The reactions were cleaned up through 
an Illustra Sephadex G50 (GE Healthcare) spin column and eluted in a final volume of 30 
µL milli-Q water. Sequencing reactions were then electrophoresed on an Applied 
Biosystems 3130xl sequencer using a 50cm array.  
MKI67 showed no PCR products of the correct size, while all other primer pairs generated 
correct sized bands, although some had other non-specific bands (Figure 5.6). Sequencing 
results (Figure 5.7) confirmed the MultiNA results; the products using primers for MKI67 
gave an incorrect sequence, while the products for the other six primer pairs had the 
correct sequences. After these results, MKI67 was excluded from any further analysis as 




Figure 5.6: MultiNA analysis of PCR products generated with different primer pairs.  
Pre-sequencing, the reactions were run on the MultiNA to confirm that the amplicons produced were of the correct 
















































Figure 5.7: Sanger sequencing and UCSC BLAT output. 
Sequencing results (above) and BLAT output from UCSC Genome Browser output (below) showing that the sequences 











5.1.10 PCR to establish efficiency values  
 
Using the pooled cDNA from the one-step kit, diluted 1:5, a two-fold dilution series with 
an annealing temperature of 62°C was carried out on the LightCycler®, in triplicate. This 
dilution series (Figure 5.8) was used to establish efficiency values produced by the Roche 
LightCycler® software (Table 5.1). All values for the six primers were close to 2 which 
indicates good efficiency. Efficiency values were used to calculate the ΔCp value based on 




Figure 5.8: Standard Curves for ACTB, CYC1, MCM2, EGFR, PCNA, and PGR were calculated to determine efficiency 
values.  
The slope of the dilution series was used to calculate the efficiency values which are used to confirm the effectiveness 






Table 5.1: Efficiency values produced by dilution series using Roche LightCycler®. 










5.2 Quantitative PCR results 
 
 
Following optimisation, qPCR for all of the samples using the six primer pairs was carried 
out. ACTB and CYC1 were candidate internal reference genes, while EGFR, MCM2, PCNA, 
and PGR were target genes.  
 
 
5.2.1 Internal references 
 
To overcome non-specific variation, for example variation in cDNA synthesis due to the 
quantity and quality of RNA or other reaction reagents, the use of at least one internal 
reference is important. This corrects for this variation by creating a ratio of target gene 
to reference.  
To select the appropriate internal reference, melt curves and amplification information 
was analysed (Figure 5.9). ACTB showed no primer dimers in the melt curve for template 
samples, however the NTC did form primer dimers with different melt temperatures. 
CYC1 primers produced numerous primer dimers, which formed in the NTC and template 
samples, which was a cause for concern. Any samples that produced primer dimers were 




Figure 5.9: Melt curves, melt peaks, and amplification plot for two internal references.  
(a) Amplification Plots, (b) Melting Peaks, and (c) Melting Curves for ACTB and CYC1, which are the two candidate 
internal references for qPCR analysis. ACTB has minimal noise, while CYC1 shows unusual activity in the melt curves, 
where two peaks were evident.  
 
Average Cp values were calculated from the triplicate Cp per person. Using one-way 
ANOVA (Figure 5.10) these values were used to compare mean Cp values per cohort, to 
determine whether the gene was expressed constitutively throughout the different 
cohorts. Both ACTB, and CYC1, had consistent expression between groups.   
 
 
Figure 5.10: Mean Cp values for each of the groups for the two candidate reference genes ACTB and CYC1.  
The mean Cp values for (a) ACTB and (b) CYC1 show no statistically significant differences between the Fertile (n=5), 
RIF (n=5), Research (n=6), and Other (n=4) groups, thus indicating that expression of  ACTB or CYC1 is stable between 




One-way ANOVA confirmed that either ACTB or CYC1 would make a suitable internal 
reference. Minor non-significant differences between groups could have been due to the 
efficiency of the cDNA synthesis and the amount of cDNA that was produced from the 
500ng of RNA.  
ACTB was chosen as the internal references for subsequent experiments, as results from 
the melt curves, amplification plots, and ANOVA tests were consistent. Additionally it had 
been used as the loading control for Western blot.  
 
5.2.2 Target genes 
 
 
Mean ΔCp values for each participant were divided by the median ΔCp from the Fertile 
group for each gene, and then results were grouped into study cohorts. The melting 
curves and amplification plots were analysed for each participant for each gene, to 
identify any non-specific amplification (Figure 5.11). Any samples that exhibited primer 




Figure 5.11: Melting curves and melt peaks of target genes.   
(a) The melting curves and peak for EGFR and (c) PCNA had no unusual amplification in any of the template samples, 
only in the NTC’s, while (b) the MCM2 and (d) PGR plots had unusual amplification in some of the samples, and so these 




5.2.3 Normalisation method 
 
The method of calculating ΔCp values was discussed in section 2.11.7. Normalisation of 
the target genes was completed by dividing the mean ΔCp value for each participant by 
the median ΔCp value of the Fertile group. This method set the results for the Fertile 





5.2.4 Non-significant results 
 
Quantitative PCR results of the target genes have shown that there was no statistically 
significant difference in the gene expression of MCM2 and EGFR between the different 
cohorts, within the endometrium (Figure 5.12). This suggest that these markers are not 






Figure 5.12: Amplification plots and box and whisker plots of gene expression for MCM2 and EGFR.  
The amplification plot of EGFR (a) and relative expression of EGFR (b), show that there is no statistically significant 
differences between the Fertile (n=5), RIF (n=5), Research (n=6), and Other (n=4) groups. This is also observed with 










5.2.5 Significant results 
 
Quantitative PCR produced statistically significant differences between groups for 
expression of PGR and PCNA (Figure 5.13). Although there was no significant difference 
between the Fertile and RIF groups, there was a significant reduction in PCNA in the 
Research group in comparison to the Fertile group. There was also a significant reduction 
of PCNA expression in the Research group in comparison to the RIF group. The Other 
group also shows to have reduced PCNA expression in comparison to the RIF group. 
Expression of PGR also shows a very similar results to PCNA, with significant down-
regulation of PGR in the Research and Other groups in comparison to the RIF and Fertile 
groups.  
 
Figure 5.13: Amplification plots and box and whisker plots of gene expression for PGR and PCNA. 
The amplification plot of PCNA (a) and relative expression of PCNA (b), show that there is a statistically significant 
decrease in expression of PCNA in the Research group (n=6) in comparison to the Fertile group (n=5), and between the 
Research and RIF groups (n=5) as well as the Other (n=4) and RIF groups. The amplification plot for PGR (c) and relative 
expression of PGR (d) showed that there was a statistically significant decrease in expression of PGR in the Other group 
in comparison to the Fertile group and RIF group, as well as a reduction in the Research group in comparison to the 




5.3  Summary of findings from quantitative PCR 
 
 
Overall, the findings from qPCR have not provided any evidence of altered gene 
expression in the RIF group in comparison to the Fertile group, and hence changes in 
expression of these genes may not be linked to infertility. However, it has given 
interesting results which draw on the idea that the women who are categorised in the 
Research and Other groups, who do not have RIF, have fertility genotypes that also affect 
the endometrium. Significant down regulation has been observed of two key markers, 
PCNA and PGR, which are important for endometrial proliferation in these women. This 
endometrial dysfunction could contribute to these women not being able to achieve 
successful implantation.  
 
5.4 Limitations of using qPCR 
 
For the optimisation procedures and final qPCR analysis, two different real-time 
machines were used. The Eco™ Illumina and the LightCycler® appeared to have slight 
temperature differences. There were differences when the samples were run on the Eco™ 
Illumina at 62°C in comparison to the LightCycler®, which meant that the annealing 
temperatures had to be altered once using the LightCycler®. 
The one-step reverse transcriptase kit used for cDNA was a pre-made master mix which 
meant that –RT reactions could not be generated. This was not ideal as the –RT is useful 
for detecting non-specific amplification, or genomic contamination. However, as the 
optimisation of the conditions for qPCR was set up using the two-step kit, conditions, such 
as the annealing temperature and cDNA dilution, were chosen to reduce non-specific 
amplification and increase specific amplification. This reduced the likelihood that non-
specific amplification would occur, even though it could not be detected.  
Ideally, looking at a tighter range of primer dilutions, annealing temperatures, and 
reagent concentrations, would have been optimal, but this was time consuming, and there 
was limited cDNA available.  
SYTO9 is a non-specific dye that binds to all double-stranded DNA, which means that 
primer dimers can form. This is an issue as it can cause interference with target gene 
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monitoring. To minimise the effect of primer dimers, melt curves were analysed for every 
sample run, and any samples that had primer dimers were excluded from analysis. 
Additionally, because of the non-specificity of the dye, only one set of primers could be 
used in each reaction. It would have been optimal to use TaqMan probes as they bind 
specifically to the target sequence, and also allow for multiple target genes to be analysed 
in one reaction. Unfortunately, this method is very expensive, and therefore was not used 
for this study.  
Mean ΔCp values per participant, per gene were used based on the replicate values. As 
mentioned in methods section 2.11.7, standard deviations were used to identify outliers. 
As these outliers were removed, as well as values that had unusual melt or amplification 
plots, some participants did not have a mean ΔCp value across the triplicate range. This 
was not optimal as some participants only had one ΔCp value, and therefore analysis was 
reliant on this single value being representative of the true crossing point. This affected 
one participant in the Other group and one in the RIF group, which only had single ΔCp 
values for PGR. Also, three participants in the RIF group and one in the Other group had 
single ΔCp values for MCM2. So PGR and MCM2 results could have been somewhat 
skewed, and so should be interpreted with care.  
For this research, whole tissue was used for RNA extraction, rather than micro-dissected 
specialised cells. Preliminary work from the LCPR group, as well as work reported in the 
literature, has tended to use micro-dissected cells. This allows the identification of the 
cell types of interest, for instance stromal, glandular, and luminal cells, and examination 
of gene expression from the cells of interest. Using whole tissues may have skewed the 
gene expression results, unlike immunofluorescence analysis, which quantifies proteins 









6 Discussion  
 
RIF is a significant problem for women going through IVF treatment. RIF is a form of 
unexplained infertility, and the literature suggests that the majority of cases are a result 
of endometrial inadequacy, where the endometrium fails to mature to a point of 
receptivity (61, 68). The endometrium must proliferate and prepare for implantation to 
occur (167), and if this process is deficient, implantation may fail. At present, the 
mechanisms behind this process are poorly understood. 
While there has been discussion regarding the potential roles of proliferation markers in 
the endometrium, their role in determining endometrial receptivity is still inconclusive 
(67, 69, 71, 72). This project sought to investigate a range of proliferation markers within 
the endometrium, in order to determine their function in the development of the 
endometrium prior to implantation, and their importance for determining endometrial 
receptivity.  
Several studies have reported that during the early-secretory phase of the menstrual 
cycle, the endometrium transitions from a non-receptive, LH+2 phase, to a receptive, 
LH+7, phase (54, 55). As the transition between these two time points occurs, there are 
alterations of different markers in the endometrium and it is hypothesised that 
dysregulation of the markers is responsible for RIF (82, 168).  
 
 
6.1 Development of methods 
 
 
Three methods were established to analyse protein and gene expression in endometrial 
samples. Immunofluorescence was previously established by the LCPR group. Western 
blotting and qPCR were optimised for this research by manipulating and testing a range 
of conditions. During the process of optimising Western blot, it became apparent that 
YWHAZ was not a suitable loading control, as it was significantly reduced in women with 
RIF. YWHAZ, or 14-3-3, operates in the cell cycle pathway and is involved in the 
mechanisms of mitosis and proliferation (Figure 1.2). In contrast, this study 
demonstrated that ACTB has consistent expression in women regardless of their fertility 
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phenotype. Additionally, using qPCR, two internal references, ACTB and CYC1, were found 
to have relatively constant expression between women with different fertility 
phenotypes, and were therefore judged to be suitable as internal references for gene 
expression analyses.  
 
6.2 Summary of findings 
 
This study researched protein expression using immunofluorescence and Western blot, 
and gene expression using qPCR. Reasonably consistent results were obtained using 
immunofluorescence and Western blot. Using immunofluorescence, it was observed that 
CCNA, PCNA, MKI67, and SMAD3 were down-regulated in women with RIF and IL1R1 
was up-regulated in this group. There were no other significant differences between 
groups for the other tested markers. PCNA and CCNA were tested using Western blots, 
which confirmed that PCNA was significantly down-regulated in the RIF group. However, 
CCNA was not significantly reduced, although there was a trend which indicated reduced 
CCNA protein expression in the RIF group. Moreover, MCM2 levels were not significantly 
different between groups when tested through Western blot and immunofluorescence, 
although the same apparent trend of reduced protein expression in the women with RIF 
was evident. PGR was observed to be significantly reduced in the women with RIF, 
however, this was not observed with immunofluorescence. Quantitative PCR showed no 
significant differences between the Fertile and RIF groups for EGFR, MCM2, PCNA, and 
PGR. A significant reduction of PGR and PCNA was identified in the Research and Other 
groups, in comparison to the Fertile and RIF groups.  
Immunofluorescence allowed visualisation and semi-quantification of processes 
occurring. It was noted that there was distinct up-regulation of proliferation markers, 
particularly in the luminal epithelium, in comparison to the other cell types. This 
observation supports the body of evidence that the luminal epithelium is the 
compartment of the endometrium that transitions to a receptive state, as it is the first 







6.3 Cell cycle pathway 
 
 
Candidate markers for this study were selected based on preliminary work by the LCPR 
group, combined with reports from previous studies that have suggested their 
importance in endometrial proliferation. The majority of these markers feature in either 
the cell cycle or focal adhesion pathways (71). Both pathways are important for 
proliferation or mitosis, and are therefore more likely to be important for endometrial 
proliferation. Our analysis has identified that PCNA, CCNA, YWHAZ, and SMAD3, which 
feature in the cell cycle, have differential expression between women with different 
fertility phenotypes. These results suggest that these markers, and therefore the cell cycle 
pathway, may be important for determining proliferation in the endometrium.  
PCNA was chosen as a candidate proliferation marker as it is expressed in fertile women 
(169) and has been previously recognised as a marker of proliferation in endometrial 
samples (97, 170). It is widely understood that PCNA is present in cells which are 
proliferating (94, 171); several studies have reported that in the normal functioning 
endometrium, PCNA is highly expressed in the stromal fibroblasts, luminal epithelium, 
and glandular epithelium during periods of proliferation, while PCNA expression is 
reduced in women with endometrial dysfunction (30, 95). Our research is consistent with 
PCNA being an established proliferation marker, as a reduction of PCNA protein 
expression was observed in women with RIF through immunofluorescence (Figure 3.3) 
and Western blot (Figure 4.10). A reduction of PCNA gene expression in the Research and 
Other groups was detected through qPCR (Figure 5.13). As it has been discussed in the 
literature that reduced PCNA is associated with endometrial dysfunction; the reduction 
of PCNA protein expression in the RIF group and PCNA gene expression in the Research 
and Other groups suggests that they may have reduced proliferation and therefore 
potentially inadequately primed endometria. This observation may at least partly 
account for implantation failure. 
SMAD3 features in the cell cycle, which influences the control of proliferation (133). It 
features as a proliferation suppressor once phosphorylated by TGFβ (134). Increased 
SMAD3 expression could indicate decreased proliferation, and this was observed in the 
Fertile cohort (Figure 3.3). This was not consistent with our other results which have 
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shown increased proliferation markers, as increased SMAD3 expression in the Fertile 
cohort suggests that these fertile women have less proliferative endometria. We can 
hypothesise that SMAD3 may be increased in the fertile women, as other proliferation 
markers (such as PCNA and CCNA) increase, to potentially control these proliferation 
markers and prevent uncontrolled proliferation. SMAD3 responds to sex hormones, 
where a reduction in E2 causes a reduction in SMAD3 (136), while an increase in P4 causes 
an increase in SMAD3 (135). As P4 is increased in the secretory phase (11), especially the 
early-secretory phase, this further supports the suggestion that SMAD3 is increased in 
fertile women at the LH+2 time point.  
 
6.4 Other important markers 
 
Western blot results indicated a reduction in PGR levels in the women with clinically 
defined RIF (Figure 4.11), and qPCR results suggested decreased PGR in the Research and 
Other groups (Figure 5.13). These findings supported the preliminary assumption that 
women in these groups had altered PGR expression, which could be a reason for their 
unexplained infertility. P4 is important for the development and proliferation of the 
endometrium for implantation by the embryo during the mid-secretory phase, as well as 
maintaining the pregnancy (11). In the normal functioning endometrium, PGR is up-
regulated in the proliferative phase of the menstrual cycle and decreased during the 
secretory phase, to assist with proliferation of the endometrium (26, 29, 30). P4 exerts its 
actions through PGR (26), therefore if there is a reduction in PGR, then proliferation and 
preparation of the endometrium may be impaired. This could be a reason why the women 
in the RIF group, who have significantly reduced PGR expression, may not be getting 
pregnant because the endometrium is inadequately prepared. Similar findings have be 
reported by Leach et al (46) who found reduced PGR expression in infertile women, 
compared to fertile women, during the WOI. 
MKI67 is a protein that is expressed in the nuclei of cells that are proliferating (104-106). 
Salmi et al (110) discussed that the expression of MKI67 is correlated with the rate of 
proliferation. This has also been reported in other studies which have identified 
increased MKI67 protein expression in the proliferative phase, and expression begins to 
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decrease during the early-secretory phase (108, 111-113). In this study, biopsies were 
taken during the early-secretory phase (LH+2), which is when proliferation is still 
occurring and MKI67 is therefore expressed. By analysing MKI67 expression at this time 
the proliferation rate could potentially be identified. Using immunofluorescence in this 
study, it was noted that there was a significant reduction of the expression of MKI67 
protein in women with RIF (Figure 3.3). This finding could be interpreted as the women 
with RIF have a reduction of proliferation. Furthermore, an apparent threshold of MKI67 
diffuse nuclear cell staining was observed, as shown in Figure 3.8, and this threshold 
value could potentially be used to identify adequate proliferation in the endometria. This 
threshold has also been observed by others and is used as a prognostic tool in a clinical 
setting for monitoring proliferation status (172-175).  
IL1R1 is an inflammatory marker that is present in the endometrium (121). Several 
studies have reported that IL1R1 is decreased during the proliferative phase and 
increased during the secretory phase of the menstrual cycle, as it is involved in preparing 
the normal functioning endometrium for implantation rather than for proliferation (122-
124). It is understood that inflammation in the endometrium is important for 
implantation success. When a Pipelle biopsy is taken, it causes an inflammatory response 
where the endometrial tissue responds by producing growth factors and inflammatory 
cytokines (176, 177). This wounding forms scar tissue within the endometrium, creating 
a hospitable environment for an embryo, and has been shown to increase IVF success by 
at least 30% (156, 176, 178). Through immunofluorescence, this study detected 
increased levels of IL1R1 in the endometrium of the women with RIF, and decreased 
levels in the fertile women, during the LH+2 phase (Figure 3.5). At this LH+2 time, it is 
assumed that proliferation is still occurring and that IL1R1 has not increased to the 
optimal maximum level for the later secretory phase. This assumption supports our 
finding of reduced IL1R1 in the Fertile cohort. Increased levels of IL1R1 in the RIF cohort 
could be explained by overexpression of this marker causing a negative effect on 
implantation success. The consequences of overexpression of IL1R1 are not documented 
in the literature, and a conclusion cannot be made as to whether IL1R1 overexpression 







Angiogenesis and the associated markers, such as VEGF and VEGFR, have been reported 
to be involved in endometrial development prior to implantation (101, 150-153). 
Interestingly in this study when using immunofluorescence, no significant difference was 
identified when comparing VEGF and VEGFR levels in Fertile and RIF cohorts. This 
indicated that VEGF, and its role in angiogenesis may not be important for proliferation 
adequacy in the endometrium. Consequently, this marker is probably not important for 
distinguishing between women with different fertility phenotypes.  
 
 
6.6 Study limitations and future directions  
 
For the purpose of this study, immunofluorescence was used as an initial method to 
observe the protein expression of 25 different candidate markers of endometrial 
proliferation. As this was a time consuming process, and Western blot and qPCR needed 
to be started, preliminary immunofluorescence results were used to select markers to 
pursue with the other two techniques. After all the immunofluorescence was completed 
and the immunofluorescence statistical analysis was repeated, it was recognised that 
some of the markers that initially appeared to be significant (MCM2, EGFR, and PGR) were 
no longer significant, while markers that were not identified as significant initially 
(SMAD3 and IL1R1) were later identified as significant. Consequently some potentially 
important markers were excluded from further analyses. In the future it would be 
valuable to run Western blots and qPCR for SMAD3 and IL1R1.  
After completing this research, additional questions require further investigation. Firstly, 
the method for detecting MKI67 requires further optimisation to establish whether it has 
an important proliferative role in the endometrium. By looking at MKI67 protein and 
gene expression, a precise threshold of proliferation, based on the percentage of MKI67 
positive cells, could be established to identify whether proliferation is occurring and 
therefore the likelihood of implantation.  
The sample sizes for the groups in this study were relatively small. This was a preliminary 
pilot study to establish methods and identify possible proliferation markers. To develop 
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these markers for a clinical setting, more participants would need to be recruited to 
increase the sample size. Additionally, other factors impacting endometrial proliferation, 
and therefore the proliferation markers, could be researched if the sample size was 
larger. For example, if there was a much larger range of women, the effects of age, 
smoking history, and other contributing factors could be used to test whether they are 
also correlated with implantation success or failure.  
In this study, differential results were observed between protein expression and RNA 
expression analyses. For protein expression, significant differences for proliferation 
markers were detected between the Fertile and RIF groups. This difference between the 
Fertile and RIF cohorts was not observed through gene expression analysis. RNA 
expression does not necessarily correlate with protein expression, as there are many 
factors regulating protein expression such as rates of translation, stability of the protein 
and RNA, and variable splicing of protein isoforms (179-181). 
Furthermore it should be recognised that immunofluorescence detected protein 
expression in a subset of endometrial cells, glandular epithelium, luminal epithelium, and 
stromal fibroblasts. A much larger number of cell types constituted the tissue used for 
Western blot and qPCR. The endometrium contains multiple different cell types which 
could have a diluting effect on gene and protein expression that was detected. Thus 
comparison of results between methods should be interpreted with care.  
 
In general, the day of cycle when the Pipelle was collected of the Research and Other 
groups was more progressed than the Fertile and RIF groups (Table 2.2). The early-
secretory, non-receptive, LH+2 phase of the menstrual cycle was of interest, as this is a 
time where proliferation still occurs (182). In comparison, during the later receptive, 
LH+7 phase, the endometrium is less proliferative while it is preparing for an embryo to 
implant. Clinical notes revealed that the day of cycle of the Research and Other women 
were closer to the mid-secretory, LH+7 phase. Results may have been skewed for these 
two groups as there is down regulation of proliferation markers at this later phase (71, 
82). This could explain the unusual results of low PGR and PCNA gene expression 
observed in these two groups in comparison to the Fertile and RIF groups. PGR and PCNA 
decrease in the mid-secretory phase (29, 71), providing an explanation as to why PGR 





This pilot study demonstrated differences in protein and gene expression between 
women with different fertility phenotypes. It was identified that the cell cycle is an 
important pathway for determining proliferation adequacy in endometrial samples, as 
markers which feature in this pathway are significantly altered depending on fertility 
outcome. Immunofluorescence and Western blot revealed that protein expression 
differed between the Fertile cohort and the RIF cohort, supporting the hypothesis that 
there may be altered expression of particular markers in the endometrium during the 
LH+2 phase between women with different fertility phenotypes. These protein and gene 
expression patterns suggest that a reduction in specific proliferation markers in the 
endometrium could cause a reduction in endometrial receptivity, and subsequently the 
likelihood of embryo implantation. It is proposed that MKI67 could be a potential marker 
for determining proliferation adequacy in endometrial samples, however methods for 
detecting this marker require further optimisation. Defining the components of 
proliferation adequacy, such as markers important for proliferation, could assist with 
developing a clinically applicable test. Ultimately, this test could identify proliferation 
failure, therefore decreased endometrial receptivity, and the consequential negative 
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